Nothing Special   »   [go: up one dir, main page]

EP3146342B1 - Thérapie personnalisée de cancer associé à une inflammation à l'aide de procédés d'évaluation de la susceptibilité d'un sujet pour le traitement avec des antagonistes/inhibiteurs egfr - Google Patents

Thérapie personnalisée de cancer associé à une inflammation à l'aide de procédés d'évaluation de la susceptibilité d'un sujet pour le traitement avec des antagonistes/inhibiteurs egfr Download PDF

Info

Publication number
EP3146342B1
EP3146342B1 EP15729350.7A EP15729350A EP3146342B1 EP 3146342 B1 EP3146342 B1 EP 3146342B1 EP 15729350 A EP15729350 A EP 15729350A EP 3146342 B1 EP3146342 B1 EP 3146342B1
Authority
EP
European Patent Office
Prior art keywords
egfr
subject
mice
inflammation
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP15729350.7A
Other languages
German (de)
English (en)
Other versions
EP3146342A1 (fr
Inventor
Maria Sibilia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medizinische Universitaet Wien
Original Assignee
Medizinische Universitaet Wien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Universitaet Wien filed Critical Medizinische Universitaet Wien
Publication of EP3146342A1 publication Critical patent/EP3146342A1/fr
Application granted granted Critical
Publication of EP3146342B1 publication Critical patent/EP3146342B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Definitions

  • the present invention relates to in vitro methods of assessing the susceptibility or responsiveness of a subject to the treatment with an epidermal growth factor receptor (EGFR) inhibitor/antagonist, as further defined in the claims, wherein the subject has been diagnosed as suffering from inflammation-associated cancer or is suspected of suffering from inflammation-associated cancer, such as hepatocellular carcinoma (HCC) or colorectal cancer.
  • EGFR epidermal growth factor receptor
  • HCC hepatocellular carcinoma
  • colorectal cancer comprise a step of determining the level of expression of EGFR in myeloid cells in a sample obtained from the subject, wherein an expression of EGFR in the myeloid cells is indicative of the subject being susceptible or responsive to the treatment with an EGFR inhibitor/antagonist.
  • the invention also relates to an EGFR inhibitor/antagonist for use in the treatment or amelioration of inflammation-associated cancer, such as HCC or colorectal cancer, in a subject that has been subjected to the aforementioned methods and has been identified in said methods as being susceptible or responsive to such treatment.
  • the invention furthermore provides in vitro methods of prognosing the survival time, the progression-free survival time or the disease course of a subject that has been diagnosed as suffering from inflammation-associated cancer or is suspected of suffering from inflammation-associated cancer, as further defined in the claims, which methods also rely on determining the expression of EGFR in myeloid cells in a sample obtained from the subject.
  • the invention relates to in vitro diagnostic methods of assessing the proneness of a subject to develop inflammation-associated cancer, such as colorectal cancer, wherein the expression of EGFR in myeloid cells in a sample from the subject is determined, as defined in the claims.
  • the invention further provides an EGFR inhibitor/antagonist for use in the prevention of inflammation-associated cancer in a subject that has been subjected to the aforementioned diagnostic methods and has been identified in said methods as being prone to develop inflammation-associated cancer.
  • HCC hepatocellular carcinoma
  • colorectal cancer poses a serious threat to human health.
  • HCC for example, is the sixth most frequent cancer with limited treatment options and poor prognosis.
  • HCC is the third most common cause of cancer-related mortality worldwide and represents the fastest growing cause of cancer-related death (Jemal, A. et al., 2011).
  • the main risk factors for HCC include hepatitis B or C virus infection, alcoholic liver injury, non-alcoholic steatohepatitis, environmental carcinogens and hereditary metabolic diseases (Whittaker, S. et al., 2010).
  • HCC almost inevitably develops in the setting of chronic hepatitis or cirrhosis, conditions regarded as preneoplastic stages (Laurent-Puig, P. et al., 2006).
  • HCC is a tumor with very heterogeneous biology and etiology, growth dynamics and outcome.
  • therapeutic approaches to HCC have been proposed (e.g., Wiedmann, M.W. et al., 2011; Chen, W.C. et al., 2010; and Hoechst, B. et al., 2008), current treatment options are limited, which may be due in part to the lack of tissue markers for patient stratification for individualized treatment.
  • liver biopsies for HCC diagnosis, which is largely based on radiological criteria (EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma, 2012).
  • Biomarker based individualized drug treatment has recently brought major breakthroughs in previously poorly controlled malignancies such as lung and breast cancer. Therefore, more work is urgently needed to better understand the relevant biological mechanisms driving HCC development and progression.
  • Cytokines such as IL-6 and IL-1 play a central role in liver carcinogenesis.
  • IL-6 is produced by Kupffer cells following stimulation with IL-1, which is released by dying hepatocytes (Grivennikov, S.I. et al., 2010; Sakurai, T. et al., 2008).
  • IL-6 is responsible for compensatory proliferation of damaged hepatocytes leading eventually to HCC development (Naugler, W.E. et al., 2007).
  • myeloid cells including macrophages in connection with tumor angiogenesis have also been described (Murdoch, C. et al., 2008).
  • JNK1, p38 and IKK ⁇ have also been shown to be involved in human HCC (Hui, L. et al., 2008; Li, H.P. et al., 2013; Wang, S.N. et al., 2012). Moreover, these signaling molecules can regulate IL-6 production in the liver, although the mechanisms are unclear.
  • EGFR signaling has also been linked with HCC pathogenesis.
  • EGFR is overexpressed in 40-70% of human HCCs (Buckley, A.F. et al., 2008), and elevated expression of the EGFR ligand TGF ⁇ has been reported in preneoplastic lesions suggesting a role for EGFR signaling in early HCC (Feitelson, M.A. et al., 2004).
  • EGFR antagonists have been shown to be effective in human HCC cells and have demonstrated therapeutic efficacy in a preventive trial in a rat HCC model (Hopfner, M. et al., 2004; Schiffer, E. et al., 2005).
  • mice lacking EGFR in different cell types of the liver were employed in order to dissect the role of different cellular players and signaling pathways in HCC development.
  • mice lacking EGFR in macrophages were found to show impaired hepatocarcinogenesis, whereas mice lacking EGFR in hepatocytes unexpectedly develop more HCC due to increased hepatocyte damage and compensatory proliferation.
  • the presence of EGFR-positive liver macrophages in HCC patients has further been found to be associated with poor survival.
  • EGFR is required in liver macrophages to transcriptionally induce IL-6, a tumor-inducing cytokine, triggering hepatocyte proliferation and HCC.
  • the present invention is based on the unexpected finding that the expression of EGFR specifically in myeloid cells that are localized in tissues affected by inflammation-associated cancer, particularly in CD68-positive macrophages (such as Kupffer cells in the case of HCC), is indicative of the corresponding subject/patient being susceptible/responsive to the treatment with an EGFR inhibitor/antagonist. Positive clinical results are to be expected in these patients who have CD68-positive macrophages in the inflammation-associated cancer tissue. This is in clear contrast to previous treatment regimens proposed in the prior art.
  • the determination of the expression of EGFR in myeloid cells thus allows to identify those subjects that can benefit from the treatment with an EGFR inhibitor/antagonist.
  • the present invention hence provides an improved personalized therapy of inflammation-associated cancer, such as HCC or colorectal cancer, based on the purposive identification of those patients that are susceptible to the treatment with an EGFR inhibitor/antagonist, as defined in the claims.
  • the present invention relates to the following items:
  • the present invention provides an in vitro method of assessing the susceptibility or responsiveness of a subject to the treatment with an EGFR inhibitor/antagonist, wherein the subject has been diagnosed as suffering from inflammation-associated cancer or is suspected of suffering from inflammation-associated cancer, the method comprising a step of determining the level of expression of EGFR in myeloid cells in a sample obtained from the subject, wherein the expression of EGFR in the myeloid cells in the sample from the subject is indicative of the subject being susceptible or responsive to the treatment with an EGFR inhibitor/antagonist.
  • the invention also relates to the method according to the above-described first aspect, wherein a higher level of expression of EGFR in the myeloid cells in the sample from the subject is indicative of a greater susceptibility or responsiveness of the subject to the treatment with an EGFR inhibitor/antagonist.
  • an in vitro method of identifying a subject that is susceptible or responsive to the treatment with an EGFR inhibitor/antagonist wherein the subject has been diagnosed as suffering from inflammation-associated cancer or is suspected of suffering from inflammation-associated cancer, the method comprising a step of determining the level of expression of EGFR in myeloid cells in a sample obtained from the subject, wherein an increased level of expression of EGFR in the myeloid cells in the sample from the subject as compared to a control expression level of EGFR in corresponding myeloid cells in a healthy subject is indicative of the subject being susceptible or responsive to the treatment with an EGFR inhibitor/antagonist.
  • the present invention provides an in vitro method of prognosing the survival time, the progression-free survival time or the disease course of a subject that has been diagnosed as suffering from inflammation-associated cancer or is suspected of suffering from inflammation-associated cancer, the method comprising a step of determining the level of expression of EGFR in myeloid cells in a sample obtained from the subject, wherein a higher level of expression of EGFR in the myeloid cells in the sample from the subject is indicative of a shorter survival time, a shorter progression-free survival time, and a worse disease course, respectively.
  • the invention relates to each one of: (i) an in vitro method of prognosing the survival time of a subject that has been diagnosed as suffering from inflammation-associated cancer or is suspected of suffering from inflammation-associated cancer, the method comprising a step of determining the level of expression of EGFR in myeloid cells in a sample obtained from the subject, wherein a higher level of expression of EGFR in the myeloid cells in the sample from the subject is indicative of a shorter survival time; (ii) an in vitro method of prognosing the progression-free survival time of a subject that has been diagnosed as suffering from inflammation-associated cancer or is suspected of suffering from inflammation-associated cancer, the method comprising a step of determining the level of expression of EGFR in myeloid cells in a sample obtained from the subject, wherein a higher level of expression of EGFR in the myeloid cells in the sample from the subject is indicative of a shorter progression-free survival time; and (iii) an in vitro method of prognosing the
  • progression-free survival time refers to the length of time starting from the determination of the level of expression of EGFR, during which time the subject lives with the inflammation-associated cancer but it does not progress.
  • the progression of the inflammation-associated cancer is preferably determined in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as described and defined in Eisenhauer, E.A. et al., 2009.
  • the inflammation-associated cancer is considered to progress if there is at least a 20% relative increase in the sum of diameters of target lesions (all lesions up to a maximum of five lesions in total and a maximum of two lesions per organ are identified as target lesions and are recorded and measured at baseline), taking as reference the smallest sum previously determined, and if, in addition to the aforementioned relative increase of 20%, the sum of diameters of target lesions demonstrates an absolute increase of at least 5 mm and/or one or more new lesions appear; if these conditions are not fulfilled, the inflammation-associated cancer does not progress.
  • the invention provides an EGFR inhibitor/antagonist for use in the treatment or amelioration of inflammation-associated cancer in a subject, wherein the subject has been subjected to a method according to the first aspect of the invention and has been identified in said method as being susceptible or responsive to the treatment with an EGFR inhibitor/antagonist.
  • the invention relates to an EGFR inhibitor/antagonist for use in the treatment or amelioration of inflammation-associated cancer in a subject, wherein the subject has been identified as being susceptible or responsive to the treatment with an EGFR inhibitor/antagonist by determining the level of expression of EGFR in myeloid cells in a sample obtained from the subject, wherein the expression of EGFR in the myeloid cells in the sample from the subject is indicative of the subject being susceptible or responsive to the treatment with an EGFR inhibitor/antagonist.
  • the invention also provides an EGFR inhibitor/antagonist for use in a method of treating or ameliorating inflammation-associated cancer in a subject that has been diagnosed as suffering from inflammation-associated cancer or is suspected of suffering from inflammation-associated cancer, the method comprising:
  • the present invention provides an in vitro diagnostic method of assessing the proneness of a subject to develop inflammation-associated cancer (preferably colorectal cancer), the method comprising a step of determining the level of expression of EGFR in myeloid cells in a sample obtained from the subject, wherein the expression of EGFR in the myeloid cells in the sample from the subject is indicative of the subject being prone to develop inflammation-associated cancer.
  • inflammation-associated cancer preferably colorectal cancer
  • the invention also relates to the method according to the above-described sixth aspect, wherein a higher level of expression of EGFR in the myeloid cells in the sample from the subject is indicative of a greater proneness of the subject to develop inflammation-associated cancer.
  • the invention provides an EGFR inhibitor/antagonist for use in the prevention of inflammation-associated cancer in a subject, wherein the subject has been subjected to a method according to the sixth aspect of the invention and has been identified in said method as being prone to develop inflammation-associated cancer.
  • the inflammation-associated cancer may be hepatocellular carcinoma (HCC), colorectal cancer (e.g., colitis-associated cancer), lung cancer (e.g., non-small cell lung cancer), breast cancer, or any other type of inflammation-associated cancer, including in particular solid tumors with macrophage infiltration.
  • HCC hepatocellular carcinoma
  • colorectal cancer e.g., colitis-associated cancer
  • lung cancer e.g., non-small cell lung cancer
  • breast cancer e.g., breast cancer
  • any other type of inflammation-associated cancer including in particular solid tumors with macrophage infiltration.
  • Cancers associated with inflammation, particularly chronic inflammation are known in the art and are described, e.g., in Shacter, E. et al., 2002.
  • the inflammation-associated cancer is HCC or colorectal cancer (such as colitis-associated cancer). More preferably, the inflammation-associated cancer is HCC.
  • the HCC is very early-stage HCC, early-stage HCC or intermediate-stage HCC, more preferably very early-stage HCC or early-stage HCC, wherein the HCC stage is preferably determined using the Barcelona-Clinic Liver Cancer (BCLC) staging system which is described in Llovet, J.M. et al., 1999 and in Pons, F. et al., 2005.
  • BCLC Barcelona-Clinic Liver Cancer
  • the sample to be used for determining the expression of EGFR in accordance with the present invention is preferably a cancer tissue biopsy sample. If the inflammation-associated cancer is HCC, it is furthermore preferred that the sample is a liver tissue sample (particularly a liver tissue biopsy sample).
  • Liver tissue samples can be obtained using, e.g., ultrasound guided fine needle biopsy.
  • fine needle biopsy aspiration is performed after local anesthesia by using a needle guide attached to the side of the ultrasound scanner, e.g., as described in Caturelli, E. et al., 2004. Further methods of performing liver biopsies are known in the art and are described, e.g., in: Bret, P.M. et al., 1986; Edoute, Y.
  • the inflammation-associated cancer is colorectal cancer, such as colitis-associated cancer
  • the sample is a colorectal tissue sample (particularly a colorectal tissue biopsy sample) or a colorectal polyp.
  • Colorectal polyps can conveniently be obtained from the subject to be examined using, e.g., colonoscopy. It is furthermore envisaged that, depending on the specific type of inflammation-associated cancer, the sample may also be a body fluid, such as a blood sample.
  • samples obtained from the subject can be used in accordance with the invention, including any of the above-mentioned specific samples, it is preferred to use two or more, particularly three or more, more preferably five or more, and even more preferably ten or more samples from the same subject.
  • the use of multiple samples from the subject allows a more accurate assessment of the susceptibility or responsiveness of the subject to the treatment with an EGFR inhibitor/antagonist or of the survival time, the progression-free survival time or the disease course of the subject.
  • the myeloid cells in which the level of expression of EGFR is to be determined, are preferably CD68-positive myeloid cells (i.e., myeloid cells expressing CD68 as defined below), more preferably CD68-positive macrophage cells, and in particular CD68-positive tissue-resident macrophage cells.
  • the myeloid cells are Kupffer cells, particularly CD68-positive Kupffer cells.
  • Kupffer cells also known as Browicz-Kupffer cells
  • Kupffer cells are specialized macrophages that line the walls of liver sinusoids. They are considered as resident macrophages of the liver and form part of the reticuloendothelial system.
  • Kupffer cells are further described and characterized in: Naito, M. et al., 1997; Naito, M. et al., 2004; and Ikarashi, M. et al., 2013.
  • the inflammation-associated cancer is colorectal cancer (e.g., colitis-associated cancer)
  • the myeloid cells are CD68-positive myeloid cells of the intestinal lamina limbal or CD68-positive macrophage cells from a colorectal polyp.
  • the inflammation-associated cancer is lung cancer, it is preferred that the myeloid cells are CD68-positive macrophage cells.
  • CD68 refers to the glycoprotein Cluster of Differentiation 68 (also known as macrosialin) of Homo sapiens, including all possible isoforms thereof, and particularly refers to a glycoprotein expressed from the gene having the Entrez Gene ID 968 or a glycoprotein expressed from the mRNA having the NCBI reference sequence NM_001251.2 or NM_001040059.1 or a glycoprotein having the NCBI reference sequence NP_001242.2 or NP_001035148.1 or a glycoprotein having the UniProtKB accession number P34810 (including any of its isoforms, such as P34810-1, P34810-2 or P34810-3).
  • CD68 is further described and characterized in Holness, C.L. et al., 1993.
  • the term “CD68” also refers to homologs and/or orthologs of the above-described human glycoprotein that are found in other (non-human) species, particularly other mammalian species, such as Pan troglodytes (Entrez Gene ID: 100615283; NCBI reference sequences: XM_003315355.1; XM_003315356.1; XP_003315403.1; XP_003315404.1) or Rattus norvegicus (Entrez Gene ID: 287435; NCBI reference sequences: NM_001031638.1; NP_001026808.1). It is to be understood that, if the subject to be examined in accordance with the present invention is a human, then the term "CD68" preferably refers to the corresponding human glycoprotein.
  • the level of expression of EGFR is determined in myeloid cells in a sample obtained from the subject to be examined.
  • the level of expression can be determined, for example, by determining the level of translation or the level of transcription of EGFR.
  • the presence and/or the amount of EGFR protein in myeloid cells in the sample can be determined or the presence and/or the amount of EGFR mRNA in myeloid cells in the sample can be established in order to determine the level of expression of EGFR. This can be accomplished using methods known in the art, as described, e.g., in Green, M.R. et al., 2012.
  • the level of expression of EGFR is determined by determining the level of translation of EGFR.
  • the level of translation of EGFR can, e.g., be determined using antibody-based assays, such as an immunohistochemical method, an enzyme-linked immunosorbent assay (ELISA) or a radioimmunoassay (RIA), wherein antibodies directed specifically against the EGFR protein to be quantified are employed, or mass spectrometry, a gel-based or blot-based assay, or flow cytometry (e.g., FACS). If the level of translation is to be determined, it may be advantageous to include one or more protease inhibitors in the sample from the subject.
  • antibody-based assays such as an immunohistochemical method, an enzyme-linked immunosorbent assay (ELISA) or a radioimmunoassay (RIA), wherein antibodies directed specifically against the EGFR protein to be quantified are employed, or mass spectrometry, a gel-based or blot-based assay, or flow cytometry (e.g., FACS).
  • ELISA enzyme-linked immunosorb
  • the level of transcription of EGFR can, e.g., be determined using a quantitative (real-time) reverse transcriptase polymerase chain reaction ("qRT-PCR") or using a microarray (see, e.g., Ding, C. et al., 2004). It is also possible to use single-cell gene expression analysis techniques, such as single-cell qRT-PCR or single-cell microarray analysis, in order to determine the level of transcription of EGFR in single myeloid cells from the sample. If the level of transcription is to be determined, it may further be advantageous to include one or more RNase inhibitors in the sample from the subject.
  • qRT-PCR quantitative (real-time) reverse transcriptase polymerase chain reaction
  • microarray see, e.g., Ding, C. et al., 2004. It is also possible to use single-cell gene expression analysis techniques, such as single-cell qRT-PCR or single-cell microarray analysis, in order to determine the level of transcription of EGFR in single
  • the level of expression of EGFR is determined by determining the level of translation of EGFR.
  • the level of translation of EGFR is determined using an antibody-based assay, mass spectrometry, a gel-based or blot-based assay, or flow cytometry, more preferably using an immunohistochemical method, an enzyme-linked immunosorbent assay, or a radioimmunoassay, even more preferably using an immunohistochemical method. It is particularly preferred to use immunohistochemical co-staining for EGFR and for CD68 to determine the level of translation of EGFR in CD68-positive myeloid cells.
  • EGFR refers to the epidermal growth factor receptor gene in Homo sapiens (Entrez Gene ID: 1956; or NCBI reference sequence: NG_007726.3), the corresponding mRNA (including all possible transcripts/splice variants, such as NCBI reference sequence NM_005228.3, NM_201282.1, NM_201283.1, or NM_201284.1), and/or the corresponding protein (including all possible isoforms, such as NP_005219.2, NP_958439.1, NP_958440.1, or NP_958441.1, and all possible mutant forms, such as any of the aforementioned isoforms having one or more of the following mutations: T790M, L861Q, G719A, G873E, L858R, V802I, G719A, G779C and/or the mutation EGFRvIII (which is described, e.g., in Wikstrand, C.J.
  • This term also refers to homologs and/or orthologs of the human gene that are found in other (non-human) species, particularly other mammalian species, as well as their corresponding mRNAs and their corresponding proteins (also including any mutant forms thereof).
  • homologs or orthologs found in other mammalian species include the epidermal growth factor receptor gene in Mus musculus (Entrez Gene ID: 13649) and in Rattus norvegicus (Entrez Gene ID: 24329) as well as the corresponding mRNAs and proteins.
  • EGFR preferably refers to the human gene, the corresponding human mRNA and/or the corresponding human protein.
  • the human EGFR protein preferably refers to a protein comprising or having the amino acid sequence NP_005219.2 or a protein comprising or having the amino acid sequence shown in SEQ ID NO: 1, and more preferably refers to a protein having the amino acid sequence shown in SEQ ID NO: 1.
  • the subject to be examined or treated in accordance with the present invention may be an animal and is preferably a mammal, most preferably a human.
  • the mammal may be, e.g., a rodent (e.g., a guinea pig, a hamster, a rat or a mouse), a murine (e.g., a mouse), a canine (e.g., a dog), a feline (e.g., a cat), a porcine (e.g., a pig), an equine (e.g., a horse), a primate, a simian (e.g., a monkey or an ape), a monkey (e.g., a marmoset or a baboon), an ape (e.g., a gorilla, a chimpanzee, an orang-utan or a gibbon), or a human.
  • a rodent e
  • the subject to be examined or treated is a subject (preferably a human) that has been diagnosed as suffering from inflammation-associated cancer.
  • the subject to be examined or treated is a subject (preferably a human) that does not (yet) suffer from inflammation-associated cancer and/or that has been diagnosed as not suffering from inflammation-associated cancer.
  • a subject suffering from an infection with hepatitis B virus (HBV), hepatitis C virus (HCV) and/or human immunodeficiency virus (HIV) is particularly prone to develop inflammation-associated cancer such as HCC. It is therefore envisaged that the subject to be examined or treated in accordance with the invention is preferably a subject (e.g., a human) diagnosed as suffering from or suspected to suffer from an infection or coinfection with HBV, HCV and/or HIV.
  • the subject to be examined or treated is a human subject that has no activating RAS gene mutation (e.g., no activating KRAS, NRAS and/or HRAS gene mutation; particularly no activating KRAS gene mutation) in the cells in the sample (which is preferably a cancer tissue biopsy sample), particularly in any inflammation-associated cancer cells in the sample.
  • activating RAS gene mutations are known in the art and may occur, in particular, as missense point mutations at one or more of the codons 12, 13, 61 and 63 (particularly at codon 12 and/or 13) of the KRAS gene, the NRAS gene and/or the HRAS gene.
  • the numbers 12, 13, 61 and 63 refer to those codons of the respective gene that encode the 12 th amino acid, the 13 th amino acid, the 61 st amino acid, and the 63 rd amino acid of the corresponding RAS protein.
  • Exemplary activating KRAS gene mutations include each one of the mutations G12A (i.e., a replacement of the codon that encodes the 12 th amino acid of the KRAS protein, which amino acid is glycine (G) in the wild-type form of KRAS, by a codon that encodes alanine), G12D, G12R, G12V, G12C, G12S, G13D, and Q61H.
  • KRAS refers to the human KRAS gene (full gene name: Kirsten rat sarcoma viral oncogene homolog; Entrez Gene ID: 3845), the corresponding mRNA (including all possible transcripts/splice variants, such as the mRNA having the NCBI reference sequence NM_004985.4 or NM_033360.3; preferably the mRNA having the NCBI reference sequence NM_004985.4), and the corresponding protein (including all possible isoforms, such as the protein having the NCBI reference sequence NP_004976.2 or NP_203524.1; preferably the protein having the NCBI reference sequence NP_004976.2).
  • NRAS refers to the human NRAS gene (full gene name: neuroblastoma RAS viral (v-ras) oncogene homolog; Entrez Gene ID: 4893), the corresponding mRNA (including all possible transcripts/splice variants, such as the mRNA having the NCBI reference sequence NM_002524.4), and the corresponding protein (including all possible isoforms, such as the protein having the NCBI reference sequence NP_002515.1).
  • HRAS refers to the human HRAS gene (full gene name: Harvey rat sarcoma viral oncogene homolog; Entrez Gene ID: 3265), the corresponding mRNA (including all possible transcripts/splice variants, such as the mRNA having the NCBI reference sequence NM_001130442.1, NM_005343.2, or NM_176795.3), and the corresponding protein (including all possible isoforms, such as the protein having the NCBI reference sequence NP_001123914.1, NP_005334.1, or NP_789765.1).
  • the subject to be examined or treated in accordance with any of the first, fourth, fifth, and seventh aspects of the invention is a human subject whose KRAS mutation status is "wild type" at codons 12 and 13 of the KRAS gene (i.e., codons 12 and 13 each encode glycine, as in the wild-type form of KRAS).
  • the subject to be examined or treated is a human subject whose KRAS mutation status is wild type at codons 12, 13, 61 and 63 of the KRAS gene (i.e., codons 12 and 13 each encode glycine, codon 61 encodes glutamine, and codon 63 encodes glutamate, as in wild-type KRAS).
  • the KRAS mutation status of the subject can be determined, e.g., using DNA that has been isolated from the sample obtained from the subject (preferably DNA that has been isolated from inflammation-associated cancer cells from said sample).
  • the KRAS mutation status and, accordingly, the presence or absence of activating mutations at the aforementioned codons of the KRAS gene can be tested using methodologies known in the art, such as PCR-based methods (e.g., amplification refractory mutation system (ARMS) PCR), nucleic acid sequencing methods (e.g., dideoxy sequencing or pyrosequencing), mutation specific hybridization, or melting point analysis.
  • Test kits that can be used for determining the KRAS mutation status are also commercially available (e.g., the QIAGEN therascreen KRAS RGQ PCR Kit or the QIAGEN therascreen KRAS Pyro Kit, both available from QIAGEN GmbH, Hilden, Germany).
  • the EGFR inhibitor/antagonist is not particularly limited and may be any agent that inhibits or antagonizes the epidermal growth factor receptor. While the terms “EGFR inhibitor” and “EGFR antagonist” are often used synonymously in the art, the term “EGFR antagonist” in a narrow sense relates to a ligand of the epidermal growth factor receptor that blocks or dampens the response mediated by an agonist (i.e., an EGFR-activating ligand, such as epidermal growth factor (EGF) or transforming growth factor alpha (TGF- ⁇ )) but does not itself provoke a response upon binding to the receptor.
  • an EGFR antagonist may be, e.g., a small molecule or an antibody, particularly a monoclonal antibody.
  • EGFR inhibitor in a narrow sense refers to an agent (typically a small molecule) that binds to the epidermal growth factor receptor and inhibits or decreases its intrinsic tyrosine kinase activity.
  • agent typically a small molecule
  • EGFR inhibitor/antagonist as used herein also relates specifically to an EGFR inhibitor and/or specifically to an EGFR antagonist in the above-defined narrow sense.
  • Exemplary EGFR inhibitors/antagonists include, inter alia, small-molecule EGFR inhibitors/antagonists, such as gefitinib, erlotinib, lapatinib, afatinib (also referred to as BIBW2992), neratinib, ABT-414, dacomitinib (also referred to as PF-00299804), AV-412, PD 153035, vandetanib, PKI-166, pelitinib (also referred to as EKB-569), canertinib (also referred to as CI-1033), icotinib, poziotinib (also referred to as NOV120101), BMS-690514, CUDC-101, AP26113 or XL647 as well as inhibitory/antagonistic antibodies, particularly inhibitory/antagonistic monoclonal antibodies, such as cetuximab, panitumumab, zalutumumab
  • the EGFR inhibitor/antagonist may also be a pharmaceutically acceptable salt of an EGFR inhibitor/antagonist, including any of the above-described specific agents.
  • the EGFR inhibitor/antagonist is selected from gefitinib, erlotinib, lapatinib, afatinib, neratinib, ABT-414, dacomitinib, AV-412, PD 153035, vandetanib, PKI-166, pelitinib, canertinib, icotinib, poziotinib, BMS-690514, CUDC-101, AP26113, XL647, cetuximab, panitumumab, zalutumumab, nimotuzumab, matuzumab, or a pharmaceutically acceptable salt of any one of the aforementioned agents (e.g., lapatinib ditosylate, PD 153035 hydrochloride, or
  • an EGFR inhibitor/antagonist including any of the above-described specific EGFR inhibitors/antagonists, which may be formed, e.g., by protonation of an atom carrying an electron lone pair which is susceptible to protonation, such as an amino group, with an inorganic or organic acid, or as a salt of a carboxylic acid group with a physiologically acceptable cation as they are well-known in the art.
  • Exemplary base addition salts comprise, for example: alkali metal salts such as sodium or potassium salts; alkaline earth metal salts such as calcium or magnesium salts; zinc salts; ammonium salts; aliphatic amine salts such as trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, procaine salts, meglumine salts, ethylenediamine salts, or choline salts; aralkyl amine salts such as N,N-dibenzylethylenediamine salts, benzathine salts, benethamine salts; heterocyclic aromatic amine salts such as pyridine salts, picoline salts, quinoline salts or isoquinoline salts; quaternary ammonium salts such as tetramethylammonium salts, tetraethylammonium salts, benzyltrimethylammonium salts, benzyltriethylam
  • Exemplary acid addition salts comprise, for example: mineral acid salts such as hydrochloride, hydrobromide, hydroiodide, sulfate salts, nitrate salts, phosphate salts (such as, e.g., phosphate, hydrogenphosphate, or dihydrogenphosphate salts), carbonate salts, hydrogencarbonate salts or perchlorate salts; organic acid salts such as acetate, propionate, butyrate, pentanoate, hexanoate, heptanoate, octanoate, cyclopentanepropionate, decanoate, undecanoate, oleate, stearate, lactate, maleate, oxalate, fumarate, tartrate, malate, citrate, succinate, glycolate, nicotinate, benzoate, salicylate, ascorbate, or pamoate (embonate) salts; sulfonate salts such as methanesulf
  • the EGFR inhibitor/antagonist may be administered per se or may be formulated as a medicament or pharmaceutical composition.
  • Such medicaments or pharmaceutical compositions may comprise one or more pharmaceutically acceptable excipients, such as carriers, diluents, fillers, disintegrants, lubricating agents, binders, colorants, pigments, stabilizers, preservatives, antioxidants, and/or solubility enhancers.
  • the pharmaceutical compositions can be formulated by techniques known in the art, such as the techniques published in Remington's Pharmaceutical Sciences, 20th Editi on.
  • the pharmaceutical compositions can be formulated as dosage forms for oral, parenteral, such as intramuscular, intravenous, subcutaneous, intradermal, intraarterial, intracardial, rectal, nasal, topical, aerosol or vaginal administration.
  • Dosage forms for oral administration include coated and uncoated tablets, soft gelatin capsules, hard gelatin capsules, lozenges, troches, solutions, emulsions, suspensions, syrups, elixirs, powders and granules for reconstitution, dispersible powders and granules, medicated gums, chewing tablets and effervescent tablets.
  • Dosage forms for parenteral administration include solutions, emulsions, suspensions, dispersions and powders and granules for reconstitution. Emulsions are a preferred dosage form for parenteral administration.
  • Dosage forms for rectal and vaginal administration include suppositories and ovula.
  • Dosage forms for nasal administration can be administered via inhalation and insufflation, for example by a metered inhaler.
  • Dosage forms for topical administration include creams, gels, ointments, salves, patches and transdermal delivery systems.
  • the EGFR inhibitor/antagonist or the above-described pharmaceutical compositions comprising one or more EGFR inhibitors/antagonists may be administered to the subject by any convenient route of administration, whether systemically/peripherally or at the site of desired action, including but not limited to one or more of: oral (e.g., as a tablet, capsule, or as an ingestible solution), topical (e.g., transdermal, intranasal, ocular, buccal, and sublingual), parenteral (e.g., using injection techniques or infusion techniques, and including, for example, by injection, e.g., subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, or intrasternal by, e.g., implant of a depot, for example, subcutaneously or intramuscular
  • EGFR inhibitors/antagonists or the pharmaceutical compositions are administered parenterally, then examples of such administration include one or more of: intravenously, intraarterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracardially, intracranially, intramuscularly or subcutaneously administering the EGFR inhibitors/antagonists or pharmaceutical compositions, and/or by using infusion techniques.
  • parenteral administration the compounds are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood.
  • the aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary.
  • the preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well known in the art.
  • the EGFR inhibitors/antagonists or pharmaceutical compositions can also be administered orally in the form of tablets, capsules, ovules, elixirs, solutions or suspensions, which may contain flavoring or coloring agents, for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications.
  • the tablets may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glycolate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included. Solid compositions of a similar type may also be employed as fillers in gelatin capsules.
  • excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine
  • disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glyco
  • Preferred excipients in this regard include lactose, starch, a cellulose, or high molecular weight polyethylene glycols.
  • the agent may be combined with various sweetening or flavoring agents, coloring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.
  • the EGFR inhibitors/antagonists or pharmaceutical compositions can be administered in the form of a suppository or pessary, or may be applied topically in the form of a gel, hydrogel, lotion, solution, cream, ointment or dusting powder. They may also be dermally or transdermally administered, for example, by the use of a skin patch.
  • sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules.
  • Sustained-release matrices include, e.g., polylactides ( US 3,773,919 ), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., 1983), poly(2-hydroxyethyl methacrylate) (Langer, R. et al., 1981; Langer, R. et al., 1982), ethylene vinyl acetate (Langer, R.
  • Sustained-release pharmaceutical compositions also include liposomally entrapped compounds.
  • Liposomes containing an EGFR inhibitor/antagonist can be prepared by methods known in the art, such as, e.g., the methods described in any one of: DE3218121 ; Epstein et al., 1985; Hwang et al., 1980; EP0052322 ; EP0036676 ; EP088046 ; EP0143949 ; EP0142641 ; JP 83-118008 ; US 4,485,045 and US 4,544,545 ; and EP0102324 .
  • the EGFR inhibitors/antagonists or pharmaceutical compositions may also be administered by the pulmonary route, rectal routes, or the ocular route.
  • they can be formulated as micronized suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzalkonium chloride.
  • they may be formulated in an ointment such as petrolatum.
  • dry powder formulations of the EGFR inhibitors/antagonists for pulmonary administration, particularly inhalation.
  • Such dry powders may be prepared by spray drying under conditions which result in a substantially amorphous glassy or a substantially crystalline bioactive powder.
  • dry powders of the EGFR inhibitors/antagonists can be made according to the emulsification/spray drying process disclosed in WO 99/16419 or WO 01/85136 .
  • Spray drying of solution formulations of the compounds of the present invention is carried out, for example, as described generally in the " Spray Drying Handbook", 5th ed., K. Masters, John Wiley & Sons, Inc., NY, NY (1991 ), and in WO 97/41833 or WO 03/053411 .
  • the EGFR inhibitors/antagonists or pharmaceutical compositions can be formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, emulsifying wax and water.
  • they can be formulated as a suitable lotion or cream, suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, 2-octyldodecanol, benzyl alcohol and water.
  • a physician will determine the actual dosage which will be most suitable for an individual subject.
  • the specific dose level and frequency of dosage for any particular individual subject may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the individual subject undergoing therapy.
  • the EGFR inhibitors/antagonists or pharmaceutical compositions can be used in combination with other therapeutic agents.
  • an EGFR inhibitor/antagonist is used in combination with a second therapeutic agent active against the same disease, the dose of each compound may differ from that when one of the compounds is used alone.
  • the combination of an EGFR inhibitor/antagonist with one or more other drugs may comprise the administration of the drug(s) with the EGFR inhibitor/antagonist. Such an administration may be simultaneous/concomitant or sequential/separate.
  • the second therapeutic agent to be administered in combination with an EGFR inhibitor/antagonist is an anticancer drug.
  • the anticancer drug may be a tumor angiogenesis inhibitor (for example, a protease inhibitor); a cytotoxic drug (for example, an antimetabolite, such as purine and pyrimidine analog antimetabolites); an antimitotic agent (for example, a microtubule stabilizing drug or an antimitotic alkaloid); a platinum coordination complex; an anti-tumor antibiotic; an alkylating agent (for example, a nitrogen mustard or a nitrosourea); an endocrine agent (for example, an adrenocorticosteroid, an androgen, an anti-androgen, an estrogen, an anti-estrogen, an aromatase inhibitor, a gonadotropin-releasing hormone agonist, or a somatostatin analogue); or a compound that targets an enzyme
  • An alkylating agent which can be used as an anticancer drug in combination with the EGFR inhibitor/antagonist may be, for example, a nitrogen mustard (such as cyclophosphamide, mechlorethamine (chlormethine), uramustine, melphalan, chlorambucil, ifosfamide, bendamustine, or trofosfamide), a nitrosourea (such as carmustine, streptozocin, fotemustine, lomustine, nimustine, prednimustine, ranimustine, or semustine), an alkyl sulfonate (such as busulfan, mannosulfan, or treosulfan), an aziridine (such as hexamethylmelamine (altretamine), triethylenemelamine, ThioTEPA (N,N'N'-triethylenethiophosphoramide), carboquone, or triaziquone), a hydrazine (such as procarbazine),
  • a platinum coordination complex which can be used as an anticancer drug in combination with the EGFR inhibitor/antagonist may be, for example, cisplatin, carboplatin, nedaplatin, oxaliplatin, satraplatin, or triplatin tetranitrate.
  • a cytotoxic drug which can be used as an anticancer drug in combination with the EGFR inhibitor/antagonist may be, for example, an antimetabolite, including folic acid analogue antimetabolites (such as aminopterin, methotrexate, pemetrexed, or raltitrexed), purine analogue antimetabolites (such as cladribine, clofarabine, fludarabine, 6-mercaptopurine (including its prodrug form azathioprine), pentostatin, or 6-thioguanine), and pyrimidine analogue antimetabolites (such as cytarabine, decitabine, 5-fluorouracil (including its prodrug forms capecitabine and tegafur), floxuridine, gemcitabine, enocitabine, or sapacitabine).
  • folic acid analogue antimetabolites such as aminopterin, methotrexate, pemetrexed, or raltitrexed
  • An antimitotic agent which can be used as an anticancer drug in combination with the EGFR inhibitor/antagonist may be, for example, a taxane (such as docetaxel, larotaxel, ortataxel, paclitaxel/taxol, or tesetaxel), a Vinca alkaloid (such as vinblastine, vincristine, vinflunine, vindesine, or vinorelbine), an epothilone (such as epothilone A, epothilone B, epothilone C, epothilone D, epothilone E, or epothilone F) or an epothilone B analogue (such as ixabepilone/azaepothilone B).
  • a taxane such as docetaxel, larotaxel, ortataxel, paclitaxel/taxol, or tesetaxel
  • a Vinca alkaloid such as vinblast
  • An anti-tumor antibiotic which can be used as an anticancer drug in combination with the EGFR inhibitor/antagonist may be, for example, an anthracycline (such as aclarubicin, daunorubicin, doxorubicin, epirubicin, idarubicin, amrubicin, pirarubicin, valrubicin, or zorubicin), an anthracenedione (such as mitoxantrone, or pixantrone) or an anti-tumor antibiotic isolated from Streptomyces (such as actinomycin (including actinomycin D), bleomycin, mitomycin (including mitomycin C), or plicamycin).
  • an anthracycline such as aclarubicin, daunorubicin, doxorubicin, epirubicin, idarubicin, amrubicin, pirarubicin, valrubicin, or zorubicin
  • a tyrosine kinase inhibitor which can be used as an anticancer drug in combination with the EGFR inhibitor/antagonist may be, for example, axitinib, bosutinib, cediranib, dasatinib, lestaurtinib, nilotinib, semaxanib, sorafenib, sunitinib, or vandetanib.
  • a topoisomerase-inhibitor which can be used as an anticancer drug in combination with the EGFR inhibitor/antagonist may be, for example, a topoisomerase I inhibitor (such as irinotecan, topotecan, camptothecin, belotecan, rubitecan, or lamellarin D) or a topoisomerase II inhibitor (such as amsacrine, etoposide, etoposide phosphate, teniposide, or doxorubicin).
  • a topoisomerase I inhibitor such as irinotecan, topotecan, camptothecin, belotecan, rubitecan, or lamellarin D
  • a topoisomerase II inhibitor such as amsacrine, etoposide, etoposide phosphate, teniposide, or doxorubicin.
  • anticancer drugs may be used in combination with the EGFR inhibitor/antagonist.
  • Such anticancer drugs may comprise biological or chemical molecules, like TNF-related apoptosis-inducing ligand (TRAIL), tamoxifen, amsacrine, bexarotene, estramustine, irofulven, trabectedin, cetuximab, panitumumab, tositumomab, alemtuzumab, bevacizumab, edrecolomab, gemtuzumab, alvocidib, seliciclib, aminolevulinic acid, methyl aminolevulinate, efaproxiral, porfimer sodium, talaporfin, temoporfin, verteporfin, alitretinoin, tretinoin, anagrelide, arsenic trioxide, atrasentan, bortezomib, carmofur,
  • biological drugs like antibodies, antibody fragments, antibody constructs (for example, single-chain constructs), and/or modified antibodies (like CDR-grafted antibodies, humanized antibodies, "full humanized” antibodies, etc.) directed against cancer or tumor markers/factors/cytokines involved in proliferative diseases can be employed in co-therapy approaches with the EGFR inhibitor/antagonist.
  • biological molecules are anti-HER2 antibodies (e.g. trastuzumab, Herceptin®), anti-CD20 antibodies (e.g.
  • rituximab Rituxan®, MabThera®, Reditux®
  • anti-CD19/CD3 constructs see, e.g., EP11071752
  • anti-TNF antibodies see, e.g., Taylor, P.C., 2003.
  • Further antibodies, antibody fragments, antibody constructs and/or modified antibodies to be used in co-therapy approaches with the EGFR inhibitor/antagonist can be found in: Taylor, P.C., 2003; Roxana, A., 2006.
  • the EGFR inhibitors/antagonists or pharmaceutical compositions are administered in combination with physical therapy, such as radiotherapy.
  • Radiotherapy may commence before, after, or simultaneously with administration of the EGFR inhibitors/antagonists or pharmaceutical compositions.
  • radiotherapy may commence 1-10 minutes, 1-10 hours or 24-72 hours after administration of the EGFR inhibitors/antagonists or pharmaceutical compositions.
  • the subject is exposed to radiation, preferably gamma radiation, whereby the radiation may be provided in a single dose or in multiple doses which are administered over several hours, days and/or weeks.
  • Gamma radiation may be delivered according to standard radiotherapeutic protocols using standard dosages and regimens.
  • treatment as in "treatment of inflammation-associated cancer” is well known in the art and implies that the corresponding disorder or disease is suspected or has been diagnosed in a subject.
  • a subject suspected of suffering from a disorder or disease typically shows specific clinical and/or pathological symptoms which a skilled person can easily attribute to a specific pathological condition (i.e., diagnose a disorder or disease).
  • the "treatment" of a disorder or disease may, for example, lead to a halt in the progression of the disorder or disease (e.g., no deterioration of symptoms) or a delay in the progression of the disorder or disease (in case the halt in progression is of a transient nature only).
  • Treatment of a disorder or disease may also lead to a partial response (e.g., amelioration of symptoms) or complete response (e.g., disappearance of symptoms) of the subject suffering from the disorder or disease.
  • “Amelioration" of a disorder or disease may, for example, lead to a halt in the progression of the disorder or disease or a delay in the progression of the disorder or disease. Such a partial or complete response may be followed by a relapse. It is to be understood that a subject may experience a broad range of responses to a treatment (e.g., the exemplary responses as described herein above).
  • Treatment of a disorder or disease may, inter alia, comprise curative treatment (preferably leading to a complete response and eventually to healing of the disorder or disease) and/or palliative treatment (including symptomatic relief).
  • prevention of a disorder or disease is well known in the art.
  • a subject suspected of being prone to suffer from a disorder or disease may benefit from a prevention of the disorder or disease.
  • the subject may have a susceptibility or predisposition for a disorder or disease, including but not limited to hereditary predisposition.
  • Such a predisposition can be determined by standard assays, using, for example, genetic markers or phenotypic indicators.
  • a disorder or disease to be prevented in accordance with the present invention has not been diagnosed or cannot be diagnosed in the subject (for example, the subject does not show any clinical or pathological symptoms).
  • prevention comprises the use of EGFR inhibitors/antagonists or corresponding pharmaceutical compositions before any clinical and/or pathological symptoms are diagnosed or determined or can be diagnosed or determined by the attending physician.
  • the method according to the first aspect of the present invention may further comprise a step of determining whether the subject is susceptible or responsive to the treatment with an EGFR inhibitor/antagonist, wherein the expression of EGFR in the myeloid cells in the sample from the subject is indicative of the subject being susceptible or responsive to the treatment with an EGFR inhibitor/antagonist.
  • the method according to the second aspect disclosed herein may further comprise a step of determining whether the subject is susceptible or responsive to the treatment with an EGFR inhibitor/antagonist, wherein an increased level of expression of EGFR in the myeloid cells in the sample from the subject as compared to a control expression level of EGFR in corresponding myeloid cells in a healthy subject is indicative of the subject being susceptible or responsive to the treatment with an EGFR inhibitor/antagonist.
  • the method according to the third aspect of the invention may further comprise a step of making a prognosis of the survival time, the progression-free survival time or the disease course of the subject, wherein a higher level of expression of EGFR in the myeloid cells in the sample from the subject is indicative of a shorter survival time, a shorter progression-free survival time, and a worse disease course, respectively.
  • determining the level of expression of EGFR refers not only to a quantitative determination of the expression of EGFR but also to a qualitative determination whether or not EGFR is expressed, regardless of the specific (quantitative) level of expression.
  • any expression of EGFR, even a very low level of expression of EGFR, in the corresponding myeloid cells in the sample from the subject is indicative of the subject being susceptible or responsive to the treatment with an EGFR inhibitor/antagonist.
  • a threshold can, however, be applied in order to improve the accuracy of the assessment whether the subject is susceptible/responsive to the treatment with an EGFR inhibitor/antagonist.
  • the expression of EGFR is determined by determining the translation of EGFR using immunohistochemical staining for EGFR, it is preferred that only the staining of at least about 5% (more preferably at least about 10%, even more preferably at least about 20%, and still more preferably at least about 30%) of the total number of myeloid cells in an immunohistochemical preparation obtained from the sample (e.g., the tissue biopsy sample) from the subject is considered to be indicative of the subject being susceptible or responsive to the treatment with an EGFR inhibitor/antagonist.
  • the expression of EGFR is determined by determining the translation of EGFR using immunohistochemical co-staining for EGFR and for CD68, it is preferred that only the double staining (for both EGFR and CD68) of at least about 5% (more preferably at least about 10%, even more preferably at least about 20%, and still more preferably at least about 30%) of the total number of CD68-stained cells in an immunohistochemical preparation obtained from the sample (e.g., the tissue biopsy sample) from the subject is indicative of the subject being susceptible or responsive to the treatment with an EGFR inhibitor/antagonist.
  • the level of expression of EGFR in myeloid cells in a sample from the subject to be examined is compared to a control expression level of EGFR in corresponding myeloid cells in a healthy subject.
  • the control expression level of EGFR can be established as part of the method according to the second aspect, which may thus include a further step of determining the level of expression of EGFR in a sample obtained from a healthy subject (i.e., a subject that does not suffer from inflammation-associated cancer) or in a mixture of samples from several healthy subjects (e.g., about 10, about 20, about 50, about 100, or about 500 healthy subjects).
  • control expression level of EGFR can also be derived from the medical literature or from experiments conducted before carrying out the method of the second aspect disclosed herein. It will be understood that the conditions under which the control expression level is or was obtained (regardless of whether it is derived from the literature or earlier experiments or whether it is determined in the course of carrying out the method according to the second aspect disclosed herein), including also the type/origin of the sample (or mixture of samples) from the healthy subject, should be identical or at least similar/comparable to the conditions used for determining the level of expression of EGFR in myeloid cells in the sample obtained from the subject to be examined. As an approximation, the control expression level of EGFR in myeloid cells of a healthy subject can normally be expected to be zero, i.e., EGFR is normally not expressed in myeloid cells of a healthy subject.
  • the present invention provides an in vitro diagnostic method of assessing the proneness of a subject to develop inflammation-associated cancer, the method comprising a step of determining the level of expression of EGFR in myeloid cells in a sample obtained from the subject, wherein the expression of EGFR in the myeloid cells in the sample from the subject is indicative of the subject being prone to develop inflammation-associated cancer.
  • the sample is a colorectal polyp and that the inflammation-associated cancer is colorectal cancer (e.g., colitis-associated cancer).
  • the subject can take appropriate measures to reduce the risk for the development of inflammation-associated cancer, which provides a substantial benefit for the subject.
  • the subject thus identified can undergo preventive medical checkups (such as, e.g., colonoscopies) more frequently and/or a tissue biopsy sample can be taken from the subject and can be examined in order to make a more accurate diagnosis.
  • the subject thus identified can also be administered an EGFR inhibitor/antagonist for prophylactic treatment, as also described in the seventh aspect of the invention.
  • the present invention furthermore relates to the use of an antibody against (i.e., binding to) the EGFR protein in an in vitro method of assessing the susceptibility or responsiveness of a subject to the treatment with an EGFR inhibitor/antagonist, which subject has been diagnosed as suffering from inflammation-associated cancer or is suspected of suffering from inflammation-associated cancer.
  • An example of such an in vitro method of assessing the susceptibility or responsiveness of a subject to the treatment with an EGFR inhibitor/antagonist is the method according to the first aspect of the invention.
  • the antibody binds specifically to the EGFR protein and may be, e.g., a polyclonal antibody or a monoclonal antibody. Preferably, the antibody is a monoclonal antibody.
  • the antibody may further be a full/intact immunoglobulin molecule or a fragment/part thereof (such as, e.g., a separated light or heavy chain, an Fab fragment, an Fab/c fragment, an Fv fragment, an Fab' fragment, or an F(ab') 2 fragment), provided that the fragment/part substantially retains the binding specificity of the corresponding full immunoglobulin molecule.
  • the antibody may also be a modified and/or altered antibody, such as a chimeric or humanized antibody, a bifunctional or trifunctional antibody, or an antibody construct (such as a single-chain variable fragment (scFv) or an antibody-fusion protein).
  • the antibody can be prepared using methods known in the art, as also described, e.g., in Harlow, E.
  • monoclonal antibodies can be prepared by methods such as the hybridoma technique (see, e.g., Kohler, G. et al., 1975), the trioma technique, the human B-cell hybridoma technique (see, e.g., Kozbor, D. et al., 1983) or the EBV-hybridoma technique (see, e.g., Cole, S.P.C. et al., 1985).
  • the term “about” refers to ⁇ 10% of the indicated numerical value, and in particular to ⁇ 5% of the indicated numerical value. Whenever the term “about” is used, a specific and preferred reference to the exact numerical value indicated is also included.
  • the present invention specifically relates to each and every combination of features and embodiments described herein, including any combination of general and/or preferred features/embodiments.
  • the invention specifically relates to all combinations of preferred features/embodiments which are described herein.
  • Example 1 EGFR is required in liver macrophages for IL-1-induced IL-6 production and hepatocellular carcinoma formation
  • mice have been previously described (Natarajan, A. et al., 2007).
  • EGFR ⁇ mac and EGFR ⁇ hep / ⁇ mac mice were generated by crossing EGFR f / f or EGFR ⁇ hep mice to LysM-Cre (Clausen, B.E. et al., 1999) transgenic mice.
  • Male mice used in this study were kept in the facilities of the Medical University of Vienna in accordance with institutional policies and federal guidelines.
  • Inducible EGFR deletion was achieved by 3 consecutive intraperitoneal (i.p.) injections with pIpC (400 ⁇ g) every third day in adult mice or by 3 consecutive i.p. injections with pIpC (150 ⁇ g) at day 9, 11, and 13 after birth.
  • the genotyping of EGFR ⁇ hep and EGFR ⁇ liv has been previously described (Natarajan, A. et al., 2007).
  • LysM-Cre double transgenic mice a reverse primer situated in the Cre transgene (Cre-R (5'-CCCAGAAATGCCAGATTACG-3') was combined with promoter specific primers for the particular transgene: Alb (5'-GCAAACATACGCAAGGGATT-3'), LysM (5'-GAGGGATGAAATTCCTGCAA-3').
  • the primers ⁇ -EGFR- F (5'-GCCTGTGTCCGGGTCTCGTCG-3')
  • ⁇ -EGFR- R (5'-CAACCAGTGCACCTAGCCTGGC-3') were used to detect deletion of EGFR ( ⁇ -EGFR ) .
  • mice were of mixed 129/Sv x C57BL/6 x CBA/J) genetic background and in all experiments EGFR expressing littermates ( EGFR f / f or Cre+ or EGFR +/+ ) served as controls to the respective EGFR deleted mice.
  • liver tumors were induced by chemical carcinogenesis in male mice according to the scheme shown in Figure 1A and quantification of liver tumors was performed as previously described (Eferl, R. et al., 2003). Mice were sacrificed when liver tumors were visible in EGFR f / f , EGFR f /+ or Cre+ littermate control mice, which occurred around 36 weeks in the Alfp-Cre, around 46 weeks in the Mx-Cre and around 63 weeks in the Alfp-Cre; LysM-Cre double transgenic background. The genetic background of the mice was mixed C57BL/6 x 129/Sv x CBA/J) but varied between the different Cre lines thus explaining the difference in the timing of tumor development. Littermates were used in all experiments.
  • Tumor incidence was also controlled in EGFR f /+ or EGFR +/+ Alfp-Cre, Mx-Cre, LysM-Cre mice to exclude cre-mediated effects.
  • Liver injury after DEN injection 100 mg/kg body weight was determined by measuring the circulating transaminases AST/ALT (Reflotron, Roche) and by quantifying necrotic areas using H&E stained sections at the time points indicated.
  • Protocols for ELISA have been previously described (Natarajan, A. et al., 2007; Lichtenberger, B.M. et al., 2010; Sibilia, M. et al., 2000; Drobits, B. et al., 2012).
  • ELISA for IL-6, IL17A, IL22, IL23 (eBioscience), amphiregulin (R&D Systems), CCL2, IL-1 ⁇ and IL-1 ⁇ (BD Biosciences-Pharmigen) were performed following the manufacturer's instructions.
  • MTT assay EZ4U, Biomedica was performed to quantify the number of viable Kupffer cells in the wells. The cytokine value was normalized to the number of viable Kupffer cells.
  • IL-1 ⁇ -F GGGCCTCAAAGGAAAGAATC
  • IL-1 ⁇ -R TACCAGTTGGGGAACTCTGC
  • IL-1 ⁇ -F CACCTTACACCTACCAGAGTGATTTG
  • IL-1 ⁇ -R IL-1 ⁇ -R
  • IL-6-F TTCCATCCAGTTGCCTTCTTGG
  • IL-6-R TTCTCATTTCCACGATTTCCCAG
  • HB-EGF-F ACCAGTGGAGAATCCCCTATAC
  • HB-EGF-R GCCAAGACTGTAGTGTGGTCA
  • TGF ⁇ -F TTGGGTACGTGGGTGTTC
  • TGF ⁇ -R ACAGGTGATAATGAGGACAGCC
  • AR-F GGTCTTAGGCTCAGGCCATTA
  • AR-R CACCGAGAAAGAAGGATGGA
  • ER-R TCACGGTTGTGCTGATAACTG
  • Hepatocytes and Kupffer cells were isolated after liver perfusion according to previously published protocols (Smedsrod, B. et al., 1985) and either directly used for further analysis or cultured as follows. Hepatocytes were plated onto collagen pre-coated cell culture dishes and cultured in HepatoZyme-SFM (Gibco) supplemented with 2 mM glutamine and 1% penicillin-streptomycin (P/S). Hepatocytes were either treated with the indicated amounts of DEN for 24 hours or with 10 ng/ml TNF ⁇ (eBioscience) in the presence of cycloheximide (100 ⁇ g/ml, Sigma) for 12 hours to study the hepatoprotective role of EGFR.
  • Hepatocytes were plated onto collagen pre-coated cell culture dishes and cultured in HepatoZyme-SFM (Gibco) supplemented with 2 mM glutamine and 1% penicillin-streptomycin (P/S). Hepatocytes were either treated with
  • Kupffer cells were isolated and plated in RPMI 1640 with 10% FCS, 2 mM glutamine, 1% P/S for at least 24 hours followed by overnight starvation (in 0.5% FCS containing medium for cytokine induction; serum-free medium for signaling experiments).
  • Kupffer cells were stimulated with IL-1 ⁇ (10 ng/ml, eBioscience), EGF (10 ng/ml, Lonza), polylC (20 ⁇ g/ml, GE Healthcare), imiquimod (12 ⁇ g/ml, Invivogen) and LPS (10 ng/ml, Invivogen) for the time period indicated.
  • Kupffer cells were pre-incubated for 5 hours (for cytokine secretion) or 1 hour (for signaling experiments) prior to stimulation with the following inhibitors: BIBW2992 (0.005-20 ⁇ M, Selleck), cetuximab (0.01-1 ⁇ g/ml, Merck), TAPI-1 (10 ⁇ M, Peptides International), SP600125 (25 ⁇ M, Calbiochem), SB203580 (10 ⁇ M, Cell Signaling), and SC-514 (100 ⁇ M, Calbiochem). Since the number of Kupffer cells which can be recovered from one mouse is very low, it was technically impossible to perform Western Blot analysis for all indicated signaling molecules on one single batch of Kupffer cells. Usually Kupffer cells from 2 livers of the same genotype were pooled together to obtain around 20-30 ⁇ g of protein lysate.
  • the 129 HCC patients of the Chinese cohort were randomly taken from the pool of HCC patients undergoing curative resection in the Eastern Hepatobiliary Surgery Hospital (Shanghai, China) between January 2002 and June 2006. None of these HCC patients received preoperative anticancer treatment.
  • the normal liver tissues were collected from the distal normal liver sections of patients undergoing surgery for liver hemangioma, who did not show any evidence of chronic liver disease.
  • the 108 HCC patients of the European cohort were randomly taken from a pool of patients who underwent orthotopic liver transplantation for HCC at the Medical University of Vienna as previously published (Sieghart, W. et al., 2011). None of these HCC patients received preoperative anticancer treatment.
  • mice per group were considered to detect a relevant difference in means of 1.5 within-group standard deviations at a two-sided significance level of 0.05 and a power of 90%, which ensures 80% power in case of a 20% drop-out rate.
  • mice per group were considered, which ensures a 90% power to detect a difference in means of 2 standard deviations at the same significance level of 0.05.
  • experiments in mice were performed at least 3 times with 3 biological replicates. Quantifications on histological samples were performed by counting/measuring at least 10 microscopic fields (HPF where indicated) on at least 3 independent tissue samples.
  • OS Overall survival
  • DFS Disease-free survival
  • OS Median survival times (OS) and their 95% confidence intervals (CIs) were reported.
  • OS Median survival times
  • CIs 95% confidence intervals
  • the chemical carcinogen diethylnitrosamine/phenobarbital (DEN/PB) (Eferl, R. et al., 2003) was used to induce HCC, as also shown in Figure 1A , which occurs in a multistep process similar to the disease in humans.
  • DEN-damaged hepatocytes undergo apoptosis and are replaced via compensatory proliferation of surviving hepatocytes, which can give rise to HCC if mutated by DEN (He, G. et al., 2011).
  • EGFR f / f are shown as control mice. They were littermates to the respective Cre positive mice resulting from EGFR f / f x EGFR f / f Cre positive breedings and received the same treatment. However, to exclude Cre-mediated effects early on it was always confirmed that all the EGFR +/+ Cre positive DEN-treated mice developed the same defects as the EGFR f / f DEN-treated controls.
  • EGFR ⁇ liv mice also referred to as EGFR ⁇ Mx mice
  • EGFR was deleted in all liver cells (i.e., hepatocytes, Kupffer cells, endothelial cells and hepatic stellate cells).
  • hepatocytes were isolated from EGFR ⁇ Mx and control mice, were stimulated for 12 hours with DEN, and immunofluorescent staining for the necrotic marker high-mobility group box 1 (HMGB1) (Degryse, B. et al., 2001) was performed, which revealed a strong necrotic response specifically in EGFR-deficient hepatocytes (see Figure 1G ).
  • HMGB1 necrotic marker high-mobility group box 1
  • EGFR-deficient hepatocytes were also more sensitive to apoptosis after TNF ⁇ /cyclohexamide (CHX) treatment, as indicated by the increase of cleaved caspase 3 (see Figure 1H ).
  • IL-1 ⁇ is mainly released by non-parenchymal cells, possibly Kupffer cells/liver macrophages, and not by damaged hepatocytes.
  • Increased IL-1 ⁇ expression was also detected in EGFR ⁇ Mx and EGFR ⁇ hep tumors (see Figure 2J ).
  • a significantly stronger increase of IL-1 ⁇ release was observed when EGFR-deficient hepatocytes were treated in vitro with DEN or TNF ⁇ (see Figures 3F and 1I ).
  • DEN or TNF ⁇ see Figures 3F and 1I
  • EGFR In both EGFR ⁇ Mx and EGFR ⁇ hep mice, EGFR protects cells from DEN-induced damage, but still EGFR plays opposing roles in promoting HCC formation illustrating the complex role of EGFR in tumorigenesis.
  • timing of EGFR deletion (late gestation in EGFR ⁇ hep mice versus 7-week old mice in EGFR ⁇ Mx mice) is responsible for the differences in HCC development between the two models, EGFR was deleted shortly after birth in EGFR f / f ; Mx-Cre mice ( EGFR ⁇ liv* ; also referred to as EGFR ⁇ Mx* ) (see Figures 1A and 4C ).
  • EGFR ⁇ Mx mice Similar to EGFR ⁇ Mx mice, also EGFR ⁇ Mx* mice developed significantly less tumors of lower mass and area than their EGFR f / f littermate controls (see Figures 4D and 4E ), indicating that not the timing of deletion, but rather the cell type, in which EGFR is deleted, accounts for the differences in HCC development between EGFR ⁇ Mx and EGFR ⁇ hep mice.
  • LysM-Cre transgenic mice were employed to generate EGFR ⁇ hep / ⁇ mac (EGFR f / f ; Alfp-Cre; LysM-Cre) mice, which lack EGFR in both hepatocytes and Kupffer cells/macrophages (see Figure 5C ). Similar to the EGFR ⁇ liv and EGFR ⁇ mac mice, EGFR ⁇ hep / ⁇ mac showed significantly fewer and smaller tumors when compared to littermate controls and EGFR ⁇ hep mice (see Figures 5D and 5E ).
  • HCC HCC formation in mice lacking EGFR specifically in parenchymal cells
  • EGFR ⁇ hep EGFR-expressing Kupffer cells/infiltrating macrophages.
  • EGFR ⁇ mac mice displayed significantly smaller tumors when compared to the respective controls (see Figures 5D and 5E ).
  • EGFR expression is induced in activated Kupffer cells/liver macrophages under pathological conditions
  • HBV Hepatitis B
  • EGFR expression was additionally investigated in an independent validation cohort of 108 European HCC patients who underwent liver transplantation for HCC (see Table 1a).
  • Table 1a EGFR expression in hepatocytes and Kupffer cells of the Chinese cohort and the European cohort (in brackets). * In 4 patients, no adjacent tissue was available.
  • AFP alpha-Fetoprotein
  • TNM classification of malignant tumors (Tumor, Node, Metastasis). # Mann-Whitney test. *includes samples where tumor and tissue adjacent to carcinoma were negative for EGFR in Kupffer cells, **includes samples where either tumor or tissue adjacent to carcinoma (or both) were positive for EGFR in Kupffer cells.
  • EGFR expression in hepatocytes of tumors did not show significant prognostic value for patient's overall survival or disease free survival after surgery (see Figures 6B-6E and Table 1a) and no significant relationship between EGFR expression in hepatocytes and clinico-pathological characteristics was found (data not shown).
  • EGFR-expressing macrophages were also present within the non-cancerous tissue adjacent to the carcinoma: 12% for the Chinese and 27% for the European cohort. It is interesting to note that in the European cohort there were more EGFR positive macrophages in the adjacent tissue, which might be due to the cirrhotic condition present in the liver of these patients.
  • the specificity of EGFR expression on CD68 positive cells was confirmed by co-staining for EGFR and CD68 in a few available fresh frozen human HCC tissue samples (see Figure 6G ).
  • EGFR-expressing Kupffer cells in HCCs were associated with poor clinical outcome of Chinese patients after surgical tumor resection and European patients after liver transplantation mirrored by significantly reduced overall survival and disease free survival (see Figures 7C-7F ).
  • ⁇ -Fetoprotein AFP
  • AFP ⁇ -Fetoprotein
  • IL-6 a major HCC promoting cytokine (Naugler, W.E. et al., 2007), is produced at high levels by Kupffer cells in response to IL-1 derived from damaged hepatocytes, and stimulates compensatory hepatocyte proliferation through IL-6R activation (Grivennikov, S.I. et al., 2010; Sakurai, T. et al., 2008).
  • IL-6 production was analyzed in mice lacking EGFR in different liver cells.
  • IL-6 serum levels were strongly induced upon DEN injection already after 6 hours only in control ( EGFR f / f ) and EGFR ⁇ hep mice (which have EGFR expressing Kupffer cells/liver macrophages), but not in EGFR ⁇ liv and EGFR ⁇ hep / ⁇ mac mice, which lack EGFR in liver macrophages (see Figure 8A ).
  • Next IL-6 mRNA levels were analyzed in liver macrophages isolated from EGFR f / f , EGFR ⁇ hep and EGFR ⁇ liv mice 6 hours after DEN injection.
  • IL-6 expression levels in EGFR-expressing Kupffer cells were significantly higher than in EGFR-deficient Kupffer cells ( EGFR ⁇ liv ) (see Figure 8B ).
  • significantly higher IL-6 levels were also found in the plasma of Chinese HCC patients displaying EGFR positive Kupffer cells in their tumors (see Figure 8C ).
  • this occurred in association with HBV infection see Figure 8D , indicating that infections and inflammatory conditions lead to upregulation of EGFR in Kupffer cells with consequent increased IL-6 production.
  • patient plasma was not available.
  • EGFR in Kupffer cells/liver macrophages is required to induce expression of IL-6, which promotes HCC formation.
  • IL-6 levels were quantified after incubation of isolated Kupffer cells/liver macrophages with IL-1 ⁇ in vitro for 6 hours.
  • IL-6 transcripts and IL-6 protein in the culture medium were induced by IL-1 ⁇ in Kupffer cells expressing EGFR, but not in EGFR-deficient liver macrophages (see Figures 8E and 8F ).
  • the levels of IL-6 mRNA detected in EGFR-deficient liver macrophages were almost as low as those seen in liver macrophages isolated from MyD88 - / - mice, which are deficient in IL-1R signaling (see Figure 8E ).
  • IL-6 production in Kupffer cells could also be prevented by BIBW2992 (EGFR kinase inhibitor) and cetuximab (EGFR-inhibiting antibody) in a dose-dependent manner (see Figures 9A and 9B ).
  • Other inflammatory cytokines such as IL-17A, IL-22 and IL-23 were not detectable in the supernatants of EGFR f / f , EGFR ⁇ liv as well as MyD88 - / - Kupffer cells following IL-1 ⁇ or EGF stimulation (data not shown).
  • IL-6 production was comparable between EGFR-expressing and EGFR-deficient Kupffer cells after stimulation with other Toll-Like Receptor (TLR) agonists that activate IL-6 production such as polylC, imiquimod and LPS (see Figure 9C ) showing that EGFR-deficient Kupffer cells are not intrinsically impaired in IL-6 production.
  • TLR Toll-Like Receptor
  • EGFR-deficient Kupffer cells cannot produce IL-6 in response to IL-1, indicating that EGFR-dependent IL-6 production is downstream of IL-1R signaling.
  • Kupffer cells release IL-6 in response to signals from damaged hepatocytes, which in turn stimulates compensatory hepatocyte proliferation.
  • Hepatocyte proliferation was therefore analyzed after short term DEN treatment in vivo in EGFR ⁇ hep , EGFR ⁇ liv and the matched EGFR f / f control mice.
  • the strongest increase of BrdU incorporation was observed in livers of EGFR ⁇ hep mice likely because DEN-induced damage is high (because of lack of EGFR in hepatocytes) and the Kupffer cells/liver macrophages still express EGFR and thereby produce IL-6 to stimulate proliferation.
  • IL-1 ⁇ -induced IL-6 production involves ADAM-17-dependent cleavage of EGFR ligands and JNK-, p38- and IKK2-signaling
  • EGFR-expressing Kupffer cells were isolated from EGFR ⁇ hep and matched control EGFR f / f mice, were incubated with IL-1 ⁇ , and EGFR ligand expression was quantified by using qRT-PCR. Except for BTC, all other EGFR ligands were significantly induced by IL-1 ⁇ (see Figure 10A ).
  • HB-EGF, TGF ⁇ , AR, and ER are proteolytically released by TACE/ADAM17 (a disintegrin and metalloprotease/TNF ⁇ converting enzyme) (Blobel, C.P., 2005), which was also induced by IL-1 ⁇ (see Figure 10A ).
  • TACE and EGFR ligands were not induced by in MyD88 - / - Kupffer cells, indicating that their induction is under direct control of IL-1R signaling (see Figure 10A ).
  • EGFR ligands and TACE were also induced by IL-1 ⁇ in Kupffer cells lacking EGFR ( EGFR ⁇ liv ) suggesting EGFR-independent transcriptional regulation (see Figure 10A ).
  • the release of the EGFR ligand AR into the culture medium of stimulated Kupffer cells was significantly increased in both EGFR expressing and EGFR-deficient Kupffer cells, but did not occur in MyD88 - / - Kupffer cells or when inhibiting TACE (TAPI-1) (see Figure 10B ).
  • AR release could also be blocked by the IKK inhibitor Sc-514, but not by inhibiting JNK or p38 signaling using SP600125 and SB203580, respectively (see Figure 10B ), demonstrating that release of AR occurs via IKK-dependent activation of TACE.
  • TAPI-1 TACE-1 inhibitor
  • BIBW2992 EGFR inhibitor
  • EGF stimulation was sufficient and equally as potent as IL-1 ⁇ in inducing IL-6 release in EGFR expressing Kupffer cells (see Figure 10C and 10D ).
  • EGF, but not IL-1 ⁇ was able to fully restore IL-6 production in MyD88 -/- Kupffer cells (see Figure 10D ).
  • MyD88 is primarily required to induce EGFR ligand production, and that EGFR activation and thereby IL-6 production is downstream of IL-1R/MyD88 signaling.
  • IL-6 production by isolated Kupffer cells/liver macrophages induced by either EGF or IL-1 ⁇ was prevented in the absence of EGFR ( EGFR ⁇ liv ) .
  • EGFR phosphorylation was analyzed in isolated Kupffer cells.
  • IL-1 ⁇ stimulation was able to induce EGFR phosphorylation in EGFR expressing Kupffer cells to a similar extent as EGF treatment. This did not occur in EGFR-deficient ( EGFR ⁇ liv ) Kupffer cells (see Figures 10E and 10F ).
  • IL-1 ⁇ -induced EGFR transactivation was blocked by p38 inhibition (SB203580) but not by JNK (SP600125) or IKK (Sc-514) inhibition indicating that activation of p38 is necessary for EGFR activation (see Figure 10E ).
  • EGFR is frequently overexpressed in human HCC, but its relevance for malignant progression is poorly understood.
  • the function of EGFR in HCC has been molecularly dissected by employing mice lacking EGFR in different liver cells, and it has been found that EGFR is expressed in Kupffer cells, where it plays a tumor-promoting role.
  • the present findings might provide a possible explanation for the poor response of unstratified advanced stage HCC patients to known EGFR targeted therapies. Based on the results provided herein, it is concluded and expected that only HCC patients with EGFR expression in liver macrophages alone or in both tumor cells and liver macrophages will show a therapeutic effect when treated with EGFR inhibitors/antagonists targeting liver macrophages. If EGFR is expressed only in tumor cells of HCC, it is expected that EGFR inhibitors/antagonists may even promote tumorigenesis, since the genetic results provided herein revealed that loss of EGFR in hepatocytes promotes HCC. Clinical follow-up studies are needed to re-evaluate the use of EGFR inhibitors in HCC, and to consider the possibility of targeting specific cell populations.
  • EGFR-expressing Kupffer cells play a tumor-promoting role only in the early stages of HCC development. Should this be the case, patients with advanced stage HCC would likely not benefit from EGFR targeted therapies, thus providing an explanation for the poor therapeutic effects seen in clinical trials with erlotinib. However, patients with HBV or HCV infections might benefit from EGFR inhibitor treatment in early disease stages to prevent HCC development. It will therefore be interesting to explore the predictive power of EGFR-expression in Kupffer cells also in patients in more advanced disease stages. Treatment of patients with EGFR positive Kupffer cells with EGFR inhibitors selectively targeting Kupffer cells could allow for improved HCC treatment in preselected patient populations.
  • EGFR plays a hepatoprotective role during DEN-induced liver damage, as absence of EGFR renders hepatocytes more susceptible to DEN-induced damage leading to increased IL-1 ⁇ secretion and subsequent enhanced stimulation of Kupffer cells (see Figure 11 ). This occurs in both mouse models lacking EGFR in parenchymal cells ( EGFR ⁇ hep and EGFR ⁇ liv mice).
  • IL-6 production in Kupffer cells is strictly dependent on the expression of EGFR and occurs in a bimodal way involving first IL-1R/MyD88 signaling followed by TACE/EGFR-L production and p38-dependent EGFR transactivation (see Figure 11 ).
  • mice lacking EGFR only in hepatocytes ( EGFR ⁇ hep ) IL-6 secretion and compensatory proliferation are elevated leading ultimately to increased HCC formation.
  • Example 2 EGFR signaling in myeloid cells of the lamina basement membrane surface potential promotes colorectal cancer development
  • IBD inflammatory bowel disease
  • CAC ulcerative colitis-associated cancer
  • DSS dextran sulfate sodium salts
  • AOM a genotoxic carcinogen
  • DSS induces colitis via tissue injury which renders the innate immune cells of the lamina intestinal exposed to the microbiota of the lumen causing their activation, which further secrete cytokines that heavily influence the course of disease pathology (Bollrath, J. et al., 2009(a); Chalaris, A. et al., 2009; Fichera, A. et al., 2007; Gabay, C., 2006; Hobbs, S.S. et al., 2011; Lee, C.H. et al., 2010).
  • EGFR epidermal growth factor receptor
  • RTK's receptor tyrosine kinases
  • the mutant EGFR is unable to protect against DSS induced colitis even upon stimulation with exogenous EGF (Egger, B. et al., 2000) and in another study it weakened re-adaptation of the intestine after surgical resection (Helmrath, M.A. et al., 1997).
  • Egger B. et al., 2000
  • Helmrath M.A. et al., 1997
  • the Egfr wa2 / wa2 mice do not show any structural defects in most organs, but are born with open eyes and develop a wavy coat like the Tgfa - / - mice which develop hair follicle defects (Luetteke, N.C. et al., 1993; Mann, G.B. et al., 1993).
  • EGFR is described to be stimulated locally in a paracrine or exocrine manner by EGF, which secreted from cells that arise temporarily in ulcerated regions (Wright, N.A. et al., 1990). Stimulation of EGFR occurs via ligands released from the cell membrane due to proteolytic cleavage of membrane bound ligand precursors by membrane bound metalloprotease-disintegrins, such as TNF-converting enzyme (TACE), also known as A Disintegrin and Metalloproteinase-17 (ADAM-17).
  • TACE TNF-converting enzyme
  • ADAM-17 A Disintegrin and Metalloproteinase-17
  • ADAM-17 hypomorphic mice ( Adam17 ex / ex ) die in utero and the few surviving ones show phenotypic similarities with Egfr - / - mice like open eyes at birth and also skin, hair follicle defects, etc (Sibilia, M. et al., 1995; Threadgill, D.W. et al., 1995; Peschon, J.J. et al., 1998).
  • ADAM17 also facilitates signaling of cytokines such as TNF ⁇ and IL-6, via ecto-domain shedding of their membrane bound precursors.
  • Both cytokines are mainly secreted by both tissues-resident, as well as infiltrating immune cells during an infection or injury which aid tissue regeneration and wound healing (Grivennikov, S. et al., 2009; Jin, X. et al., 2010). Additionally, they have also been implicated in prognosis of colitis, IBD and CAC as mice deficient in IL-6 show reduced tumor burden (Grivennikov, S. et al., 2009; Putoczki, T.L. et al., 2013). Moreover, elevated serum levels of IL-6 have been directly correlated with poor clinical prognosis in human cancers (Kim, S. et al., 2008).
  • IL-6 trans-signaling pathway Another signaling pathway currently believed to be active in such pathological conditions (Sibilia, M. et al., 1995; Threadgill, D.W. et al., 1995; Peschon, J.J. et al., 1998) is the IL-6 trans-signaling pathway, where IL-6 signals via its soluble IL6 receptor (IL6R), generated by ADAM17-mediated proteolytic cleavage in cells that do not express the membrane-bound IL6R, further leading to STAT3 activation via membrane-bound glycoprotein-130 (gp130). Inhibition of IL-6 trans-signaling by exogenous administration of gp130 in a mouse model of CAC led to substantial decrease of both colitis as well as tumor development (Kim, S. et al., 2008; Matsumoto, S. et al., 2010).
  • the intestinal mucosa is composed of a variety of cells, like IECs, which aid in the absorption of food, as well as non-epithelial cells present in the lamina basement, which are of both myeloid and hematopoietic origin, that serve to protect the intestinal lining during an infection or epithelial damage.
  • a tumor though mainly composed of cells of epithelial origin, also contains cells of hematopoietic origin including myeloid cells and tumor associated immune cells in its stroma, which have been described to heavily influence the progression of tumors (Danese, S. et al., 2010; Garlanda, C. et al., 2007).
  • conditional knock-out mice were employed, in which EGFR was selectively deleted on IECs and myeloid lineage cells. It has been demonstrated for the first time that EGFR expression on myeloid cells of the lamina intestinal injury is an important factor in prognosis of colitis and the risk of developing CAC. Moreover, the observations made herein describe a hitherto unknown barrier protective role of EGFR via IL-6 production in non-IECs intestinal injury, which is also an important requirement for survival and subsequent proliferation of transformed preneoplastic colon epithelial cells.
  • mice All animal experiments conducted were compliant with federal laws and guidelines of the Medical University of Vienna. Egfr f / f mice (Natarajan, A. et al., 2007) were bred with hemizygous Villin-Cre (el Marjou, F. et al., 2004) and LysozymeM-Cre transgenic mice (Clausen, B.E.
  • Villin-cre Egfr f / + mice or LysM-cre Egfr f / + mice were further bred to generate homozygous Egfr f / f mice expressing either Villin-cre ( Egfr ⁇ IEC ) or LysM-cre ( Egfr ⁇ MYL ).
  • Mice were genotyped by PCR for the respective cre transgenes and cre negative littermates were used as controls.
  • Egfr + , Egfr f and Egfr ⁇ alleles were detected by PCR using the following primers R4: GCCTGTGTCCGGGTCTCGTCG, R6: CAACCAGTGCACCTAGCCTGG and Egfr-fwd1: AAGTTTAAGAAACCCCGCTCTACT.
  • Apc Min/+ mice were genotyped as described in Musteanu, M. et al., 2010.
  • IECs Intestinal epithelial cells
  • Colitis was induced by administering 2.5% dextran sulfate sodium salt (DSS) (MP Biomedicals, 0216011080) in autoclaved drinking water for 5 d followed by 5 d of normal water (Chalaris, A. et al., 2010). Colon tumors in mice were induced as previously described (Wirtz, S. et al., 2007; Tanaka, T. et al., 2003). Briefly, mice were injected i.p. with 7.5 mg/kg azoxymethane (AOM) (Sigma-Aldrich, A5486) followed by repeated administration of DSS. 300 U recombinant mouse IL-6 (ImmunoTools GmbH, Germany) was administered by oral gavage. Egfr f / + Cre positive tumors were comparable to wild-type tumors and were thus analysed as controls.
  • DSS dextran sulfate sodium salt
  • mice were injected with 10 mg/kg BrdU 2.5 hrs prior to sacrifice.
  • the colons were extracted, flushed with ice cold PBS to remove feces, fixed overnight at 4°C in neutral buffered 4% formaldehyde as "Swiss Rolls", which were further dehydrated, embedded in paraffin and sectioned. Sections were stained with Haematoxylin and Eosin (Sigma), Alcian blue, Giemsa and PAS.
  • Colitis severity and tumor stage were scored and graded by pathologists in a blinded manner according to previously described criteria (Dube, P.E. et al., 2012; Musteanu, M. et al., 2010).
  • mice were orally gavaged with 60 mg/kg FITC-Dextran (Sigma FD4), food and water were withdrawn 4 h prior to gavage.
  • FITC levels were determined in the serum 4 h post gavage by absorption at 488 nm using standard dilutions of FITC-Dextran as reference.
  • mice with conditional EGFR deletion in intestinal epithelial cells (Egfr ⁇ IEC ) were generated by breeding Egfr f / f mice with Vil-Cre mice that start to express Cre recombinase around E10 (el Marjou, F. et al., 2004). Egfr ⁇ IEC mice were born at Mendelian ratios (data not shown).
  • IHC immunohistochemistry
  • hypomorphic Egfr wa2 / wa2 mice were used which display defective EGFR signaling because of a point mutation in the EGFR (Threadgill, D.W. et al., 1995).
  • Egfr ⁇ IEC mice showed no significant loss of body weight during the entire period of DSS administration (see Figure 12B ). Histological analysis revealed that the inflamed colons of Egfr ⁇ IEC mice were comparable to those of Egfr f / f mice (see Figures 12E, 12F and 12H ). These data indicate that EGFR signaling in IECs does not protect from DSS-induced colitis.
  • Egfr wa2 / wa2 mice harbor hypomorphic EGFR alleles in all body cells including that of the lamina basement. It was reasoned that the obvious difference in the DSS response between Egfr wa2 / wa2 and Egfr ⁇ IEC mice might be due to reduced EGFR signaling in lamina intestinal cells of Egfr wa2 / wa2 mice. Therefore, mice deficient for EGFR in myeloid cells ( Egfr ⁇ MYL ) were generated by breeding Egfr f / f mice with LysM-Cre mice. As expression of LysM-cre starts early during prenatal development (Clausen, B.E.
  • Egfr deletion should occur in all myeloid lineages of Egfr ⁇ MYL mice in utero including tissue resident macrophages.
  • Conditional deletion of Egfr in myeloid cells was confirmed by PCR and qRT-PCR on genomic DNA and mRNA extracted from cultured bone marrow derived macrophages (BMDM) (see Figures 21A and 21B ).
  • BMDM bone marrow derived macrophages
  • IHC analysis of DSS-treated colons showed a significant reduction of EGFR expression in lamina limba cells of Egfr ⁇ MYL mice (see Figure 21C ), while IECs maintained expression of EGFR.
  • Egfr ⁇ MYL mice were born at mendelian ratios and displayed no reduced viability or pathological abnormalities after birth. Histological examination of adult Egfr ⁇ MYL mice showed proper development of crypt structure and crypt cellular composition in both colon and small intestine (see Figures 21D and 21E ).
  • DSS-induced colitis was investigated in Egfr ⁇ MYL mice. Similar to Egfr wa2 / wa2 mice, administration of DSS induced profound weight loss of Egfr ⁇ MYL mice (see Figure 12B ) which was accompanied by severe diarrhea and blood in the feces (data not shown). Histological examination showed extensive inflammation with complete loss of the epithelium and large ulcerated regions (see Figures 12G and 12H ). DSS targets the crypt epithelial cells and alters the intestinal barrier permeability (Wirtz, S. et al., 2007; Chalaris, A. et al., 2010).
  • epithelial barrier function measured by oral administration of FITC-Dextran was defective in Egfr ⁇ MYL and Egfr wa2 / wa2 mice.
  • Egfr ⁇ MYL and Egfr wa2 / wa2 mice showed significantly higher levels of FITC-Dextran in the blood serum during colitis (see Figure 13B ) demonstrating loss of barrier integrity.
  • Egfr ⁇ IEC mice showed reduced levels of FITC-Dextran in the blood serum which is consistent with a previous study which demonstrated that inhibition of EGFR prevented loss of barrier permeability (Fasano, A., 2012; Tripathi, A. et al., 2009).
  • Crypt cell proliferation is an important factor contributing to intestinal homeostasis and epithelial regeneration during mucosal injury.
  • Analysis of BrdU incorporation showed significantly reduced BrdU-positive nuclei in the crypts of Egfr ⁇ MYL mice when compared with Egfr f / f mice.
  • the numbers of proliferating nuclei in Egfr ⁇ IEC mice were comparable with genetic controls (see Figures 13C and Figure 22A ).
  • it was stained for cleaved Caspase-3 to investigate apoptosis rates in the colon and no major differences were observed between Egfr ⁇ MYL and Egfr ⁇ IEC mice see Figures 13D and 22B ).
  • Chronic colitis is a significant risk factor for development of colorectal cancer and inhibition of EGFR signaling by cetuximab is used for treatment of metastatic CRC.
  • the occurrence of colon tumors was therefore investigated using the AOM-DSS model for colitis-associated colorectal cancer (Wirtz, S. et al., 2007; Tanaka, T. et al., 2003).
  • Tumor multiplicity and tumor size was similar in Egfr ⁇ IEC and Egfr f / f mice indicating that EGFR signaling in epithelial cells is not required for CRC formation.
  • mice remained tumor-free in Egfr ⁇ MYL and Egfr wa2 / wa2 mice, respectively (see Figure 23A ).
  • Tumors in all genotypes were predominantly low-grade adenomatous lesions, with Egfr ⁇ MYL mice having the highest proportion (see Figures 14E and 23B ). Only a minor percentage of tumors progressed to high-grade adenomas or adenocarcinomas.
  • EGFR signaling in myeloid cells promotes STAT3 activation in colorectal tumor cells
  • STAT3 activation was therefore assessed in mouse tumors by IHC for tyrosine-705-phosphorylated STAT3 (pY-Stat3).
  • epithelial ablation of EGFR did not affect STAT3 activation and Egfr ⁇ IEC mice showed comparable numbers of pY-STAT3 positive nuclei when compared with controls.
  • tumors from Egfr wa / lwa2 mice and Egfr ⁇ MYL mice showed significant reduction of nuclear pY-STAT3 when compared with corresponding control mice (see Figures 15A and 15D ).
  • Egfr wa2 / wa2 and Egfr ⁇ MYL tumors showed decreased expression of the anti-apoptotic protein Survivin, a downstream target of STAT3 (see Figures 15B and 15E ).
  • FIGS 15B and 15E show that EGFR signaling in myeloid stromal cells promotes STAT3 activation and STAT3-dependent expression of Survivin in colorectal tumor cells.
  • activation of ⁇ -Catenin was elevated in Egfr wa2 / wa2 and Egfr ⁇ MYL tumors when compared with corresponding control and Egfr ⁇ IEC tumors. This response might represent a compensatory reaction triggered by loss of oncogenic STAT3 activity (see Figures 15C and 15F ).
  • EGFR signaling in myeloid cells promotes STAT3 activation via regulation of IL-6 production
  • IL-6 levels were measured because it has been demonstrated that IL-6/STAT3 protects from DSS-induced colitis (Grivennikov, S. et al., 2009). Interestingly, serum IL-6 levels were significantly reduced in Egfr wa2 / wa2 and Egfr ⁇ MYL mice (see Figure 17A ) but not in Egfr ⁇ IEC mice. This data indicates that the observed phenotypes of Egfr wa2 / wa2 and Egfr ⁇ MYL mice in colitis and tumor formation are due to reduced IL-6 production by EGFR-deficient myeloid cells. To test this hypothesis, recombinant IL-6 was administered orally during DSS treatment.
  • IL-6 was able to protect Egfr ⁇ MYL mice from DSS-induced weight loss (see Figure 17B ) while Egfr wa2 / wa2 mice were partially rescued. Although the severity of inflammation was similar in all genotypes (see Figure 17C ), administration of IL-6 decreased the number of ulcers in Egfr ⁇ MYL mice (see Figure 17D ) and protected from loss of epithelial barrier function (see Figure 17E ).
  • IL-6 treatment was also able to fully and partially restore epithelial proliferation during colitis in Egfr ⁇ MYL and Egfr wa2 / wa2 mice, respectively (see Figures 18A and 26A ), whereas apoptosis was not affected (see Figures 18B and 26B ).
  • IL-6 decreased apoptosis in Egfr ⁇ IEC mice which might be a due to a cell autonomous effect.
  • pY-STAT3 nuclear localization was significantly reduced during DSS treatment in crypts of vehicle treated Egfr ⁇ MYL mice (see Figures 18C and 18D ) which was fully restored upon IL-6 administration.
  • the IL-6 family of cytokines has been described to play a pro-proliferative role in many inflammation driven cancers and regulate epithelial barrier function (Chalaris, A. et al., 2009; Gabay, C., 2006; Grivennikov, S. et al., 2009; Jin, X. et al., 2010; Putoczki, T.L. et al., 2013; Becker, C. et al., 2005; Bromberg, J. et al., 2009; Grivennikov, S.I. et al., 2011; Neurath, M.F. et al., 2011; Reinecker, H.C.
  • IL-6 is mainly produced by the innate immune cells of the lamina basement which promotes survival and proliferation of IECs, it is considered that selective deletion of EGFR in these cells of myeloid origin renders them unable to secrete IL-6.
  • no apparent differences have been observed in response of Egfr ⁇ IEC mice to DSS treatment in terms of weight loss and proliferation of IECs. This effect can be attributed to the expression of EGFR on the lamina intestinal cells of these mice, which are able to secrete IL-6, thereby inducing epithelial proliferation and subsequently, healing of the wounds caused by DSS.
  • mice expressing a hypomorphic ADAM17 described extensively its role in IBD (Chalaris, A. et al., 2010). These mice showed increased susceptibility to DSS treatment with severe weight loss, inflammation, extensive damage of the colonic mucosa, decreased proliferation and increased permeability of intestinal barrier, a phenotype similar to Egfr ⁇ MYL mice. This increased susceptibility to colitis was due to inability to cleave EGFR activating ligands, as exogenous supplementation of TGF ⁇ lead to a partial rescue of the symptoms (Chalaris, A. et al., 2010).
  • results provided herein underscore the need for a more targeted cell specific anti-tumor therapy unlike the conventional approach, which also entails pervasive effects, as the treatment does not always lead to a favorable outcome.
  • the present results indicate that the determination of the expression of EGFR in myeloid cells can advantageously be used to identify those patients suffering from inflammation-associated cancer such as colorectal cancer who are susceptible to the treatment with an EGFR inhibitor/antagonist.
  • the present invention thus provides an improved personalized therapy of inflammation-associated cancer such as colorectal cancer, which is to be expected to yield improved clinical results, particularly in patients having CD68-positive myeloid cells in the inflammation-associated cancer tissue.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (15)

  1. Procédé in vitro pour évaluer la sensibilité ou la réponse d'un sujet au traitement par un inhibiteur/antagoniste du récepteur du facteur de croissance épidermique (EGFR), où le sujet a été diagnostiqué comme souffrant d'un cancer associé à une inflammation ou est suspecté de souffrir d'un cancer associé à une inflammation, le procédé comprenant une étape consistant à déterminer le taux d'expression de l'EGFR dans des cellules myéloïdes dans un échantillon obtenu à partir du sujet, où l'expression de l'EGFR dans les cellules myéloïdes dans l'échantillon du sujet est indicative du fait que le sujet est sensible ou répondeur au traitement par un inhibiteur antagoniste de l'EGFR.
  2. Procédé in vitro pour pronostiquer la durée de survie, la durée de survie sans progression ou l'évolution de la maladie d'un sujet qui a été diagnostiqué comme souffrant d'un cancer associé à une inflammation ou est suspecté de souffrir d'un cancer associé à une inflammation,
    le procédé comprenant une étape consistant à déterminer le taux d'expression du récepteur du facteur de croissance épidermique (EGFR) dans des cellules myéloïdes dans un échantillon obtenu à partir du sujet, où un taux d'expression de l'EGFR plus élevé dans les cellules myéloïdes dans l'échantillon du sujet est indicatif d'une durée de survie plus courte, d'une durée de survie sans progression plus courte, et d'une plus mauvaise évolution de la maladie, respectivement.
  3. Procédé selon la revendication 1 ou 2, dans lequel l'échantillon est un échantillon de biopsie d'un tissu cancéreux.
  4. Procédé selon l'une quelconque des revendications 1 à 3, dans lequel les cellules myéloïdes sont des cellules macrophages positifs pour CD68.
  5. Procédé selon l'une quelconque des revendications 1 à 4, dans lequel le cancer associé à une inflammation est un carcinome hépatocellulaire, et/ou dans lequel l'échantillon est un échantillon de tissu hépatique, et/ou dans lequel les cellules myéloïdes sont des cellules de Kupffer.
  6. Procédé selon l'une quelconque des revendications 1 à 4, dans lequel le cancer associé à une inflammation est le cancer colorectal qui est de préférence un cancer associé à une colite, et/ou dans lequel l'échantillon est un échantillon de tissu colorectal ou un polype colorectal, et/ou dans lequel les cellules myéloïdes sont des cellules myéloïdes positives pour CD68 de la lamina propria intestinale.
  7. Procédé de diagnostic in vitro pour évaluer la susceptibilité d'un sujet à développer un cancer associé à une inflammation,
    le procédé comprenant une étape consistant à déterminer le taux d'expression du récepteur du facteur de croissance épidermique (EGFR) dans des cellules myéloïdes dans un échantillon obtenu à partir du sujet, où l'expression de l'EGFR dans les cellules myéloïdes dans l'échantillon du sujet est indicative du fait que le sujet est susceptible de développer un cancer associé à une inflammation.
  8. Procédé selon la revendication 7, dans lequel le cancer associé à une inflammation est le cancer colorectal qui est de préférence un cancer associé à une colite, et/ou dans lequel l'échantillon est un polype colorectal.
  9. Procédé selon l'une quelconque des revendications 1 à 8, dans lequel le taux d'expression de l'EGFR est déterminé en déterminant le taux de traduction de l'EGFR,
    dans lequel le taux de traduction est de préférence déterminé en utilisant un essai à base d'anticorps, la spectrométrie de masse, un essai basé sur un gel ou basé sur un blot, ou la cytométrie en flux, et dans lequel le taux de traduction, de manière davantage préférée, est déterminé en utilisant un procédé d'immunohistochimie, un test d'immunoabsorption enzymatique, ou un test radioimmunologique.
  10. Procédé selon l'une quelconque des revendications 1 à 8, dans lequel le taux d'expression de l'EGFR est déterminé en déterminant le taux de transcription de l'EGFR,
    dans lequel le taux de transcription est de préférence déterminé en utilisant une réaction en chaîne par polymérase-transcriptase inverse quantitative ou un microréseau.
  11. Procédé selon l'une quelconque des revendications 1 à 10, dans lequel le sujet est un humain, et dans lequel le sujet est de préférence un humain qui a été diagnostiqué comme souffrant ou est suspecté de souffrir d'une infection par le virus de l'hépatite B, le virus de l'hépatite C et/ou le VIH.
  12. Inhibiteur/antagoniste de l'EGFR destiné à être utilisé dans le traitement ou l'amélioration d'un cancer associé à une inflammation chez un sujet, où le sujet a été soumis au procédé selon la revendication 1 ou selon l'une quelconque de ses revendications dépendantes 3 à 6 ou 9 à 11 et a été identifié dans ledit procédé comme étant sensible ou répondeur au traitement par un inhibiteur/antagoniste de l'EGFR.
  13. Inhibiteur/antagoniste de l'EGFR destiné à être utilisé dans un procédé de traitement ou d'amélioration d'un cancer associé à une inflammation chez un sujet qui a été diagnostiqué comme souffrant d'un cancer associé à une inflammation ou est suspecté de souffrir d'un cancer associé à une inflammation, le procédé comprenant :
    - la détermination du taux d'expression du récepteur du facteur de croissance épidermique (EGFR) dans des cellules myéloïdes dans un échantillon obtenu à partir du sujet ;
    - le fait de déterminer si le sujet est sensible ou répondeur au traitement par un inhibiteur/antagoniste de l'EGFR ou non, où l'expression de l'EGFR dans les cellules myéloïdes dans l'échantillon du sujet est indicative du fait que le sujet est sensible ou répondeur au traitement par un inhibiteur antagoniste de l'EGFR ; et
    - l'administration d'un inhibiteur/antagoniste de l'EGFR au sujet si le sujet a été identifié comme étant sensible ou répondeur au traitement par un inhibiteur/antagoniste de l'EGFR.
  14. Inhibiteur/antagoniste de l'EGFR destiné à être utilisé dans la prévention d'un cancer associé à une inflammation chez un sujet, où le sujet a été soumis au procédé selon la revendication 7 ou selon l'une quelconque de ses revendications dépendantes 8 à 11 et a été identifié dans ledit procédé comme étant susceptible de développer un cancer associé à une inflammation.
  15. Procédé selon la revendication 1 ou selon l'une quelconque de ses revendications dépendantes 3 à 6 ou 9 à 11 ou inhibiteur/antagoniste de l'EGFR destiné à être utilisé selon l'une quelconque des revendications 12 à 14, où l'inhibiteur/antagoniste de l'EGFR est sélectionné parmi le géfitinib, l'erlotinib, le lapatinib, l'afatinib, le nératinib, ABT-414, le dacomitinib, AV-412, PD 153035, le vandétanib, PKI-166, le pélitinib, le canertinib, l'icotinib, le poziotinib, BMS-690514, CUDC-101, AP26113, XL647, le cétuximab, le panitumumab, le zalutumumab, le nimotuzumab, le matuzumab, ou un sel de ceux-ci pharmaceutiquement acceptable.
EP15729350.7A 2014-05-22 2015-05-21 Thérapie personnalisée de cancer associé à une inflammation à l'aide de procédés d'évaluation de la susceptibilité d'un sujet pour le traitement avec des antagonistes/inhibiteurs egfr Not-in-force EP3146342B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14169512.2A EP2947460A1 (fr) 2014-05-22 2014-05-22 Thérapie personnalisée de cancer associé à une inflammation à l'aide de procédés d'évaluation de la susceptibilité d'un sujet pour le traitement avec des antagonistes/inhibiteurs EGFR
PCT/EP2015/061220 WO2015177266A1 (fr) 2014-05-22 2015-05-21 Thérapie personnalisée de cancer associé à une inflammation, utilisant des procédés d'évaluation de vulnérabilité d'un sujet au traitement avec des inhibiteurs/antagonistes de egfr

Publications (2)

Publication Number Publication Date
EP3146342A1 EP3146342A1 (fr) 2017-03-29
EP3146342B1 true EP3146342B1 (fr) 2018-12-19

Family

ID=50771154

Family Applications (2)

Application Number Title Priority Date Filing Date
EP14169512.2A Withdrawn EP2947460A1 (fr) 2014-05-22 2014-05-22 Thérapie personnalisée de cancer associé à une inflammation à l'aide de procédés d'évaluation de la susceptibilité d'un sujet pour le traitement avec des antagonistes/inhibiteurs EGFR
EP15729350.7A Not-in-force EP3146342B1 (fr) 2014-05-22 2015-05-21 Thérapie personnalisée de cancer associé à une inflammation à l'aide de procédés d'évaluation de la susceptibilité d'un sujet pour le traitement avec des antagonistes/inhibiteurs egfr

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP14169512.2A Withdrawn EP2947460A1 (fr) 2014-05-22 2014-05-22 Thérapie personnalisée de cancer associé à une inflammation à l'aide de procédés d'évaluation de la susceptibilité d'un sujet pour le traitement avec des antagonistes/inhibiteurs EGFR

Country Status (3)

Country Link
US (1) US10309966B2 (fr)
EP (2) EP2947460A1 (fr)
WO (1) WO2015177266A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR110351A1 (es) * 2016-12-13 2019-03-20 Bristol Myers Squibb Co COMPUESTOS DE HETEROARILO SUSTITUIDOS CON FOSFINÓXIDO ALQUILAMIDA COMO MODULADORES DE RESPUESTAS DE IL-12, IL-23 Y/O IFNa
KR102213040B1 (ko) * 2017-12-20 2021-02-05 한국원자력의학원 방사선 손상 보호 또는 완화, 및 폐섬유화 예방 또는 치료 용도
SG11202012067YA (en) * 2018-06-25 2021-01-28 Spectrum Pharmaceuticals Inc Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
WO2024158827A2 (fr) * 2023-01-23 2024-08-02 The Trustees Of Columbia University In The City Of New York Ciblage de l'interaction de lymphocytes treg et de cellules stellaires hépatiques dans la fibrose hépatique et la résistance à l'insuline

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (fr) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipides et composés tensio-actifs en phase aqueuse
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0142641B1 (fr) 1983-09-26 1991-01-16 Udo Dr. Ehrenfeld Moyen et produit pour le diagnostic et la thérapie de tumeurs ainsi que pour le traitement de déficiences du système immunitaire cellulaire et humoral
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
RS50182B (sr) 1997-09-29 2009-05-06 Nektar Therapeutics, Perforisane mikročestice i postupci za njihovu primenu
PT1071752E (pt) 1998-04-21 2003-11-28 Micromet Ag Polipeptidos especificos para cd19xcd3 e suas utilizacoes
WO2001085136A2 (fr) 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Poudres a base de phospholipides permettant de distribuer un medicament
CA2468958C (fr) 2001-12-19 2012-07-03 Nektar Therapeutics Administration pulmonaire d'aminoglycosides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
WO2015177266A1 (fr) 2015-11-26
US20170184595A1 (en) 2017-06-29
EP2947460A1 (fr) 2015-11-25
EP3146342A1 (fr) 2017-03-29
US10309966B2 (en) 2019-06-04

Similar Documents

Publication Publication Date Title
JP7550193B2 (ja) Ｐｄ－１遮断による免疫療法の癌奏効の決定因子
CN107787373B (zh) 法尼基转移酶抑制剂在制备用于治疗癌症的药物中的用途
RU2706968C2 (ru) Диагностические способы и композиции для лечения глиобластомы
JP2013520958A (ja) 上皮間葉転換のバイオマーカーとしてａｘｌを使用する方法
JP2019531699A (ja) Ｎｒｆ２及びその遺伝子の下流標的遺伝子の発現状態及び変異状態によるがんの診断及び治療方法
KR20130126587A (ko) 항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
KR20190015408A (ko) 종양을 치료하는 방법에 사용하기 위한 항-pd-1 항체
EP3146342B1 (fr) Thérapie personnalisée de cancer associé à une inflammation à l'aide de procédés d'évaluation de la susceptibilité d'un sujet pour le traitement avec des antagonistes/inhibiteurs egfr
KR20230015888A (ko) 사시투주맙 고비테칸 요법에 대한 바이오마커
AU2022218493A1 (en) Compounds and compositions useful for treating or preventing cancer metastasis, and methods using same
US20230213520A1 (en) In vitro method for the prognosis of disease progression in a patient that suffers from or is at risk of developing a solid tumor
US10220091B2 (en) Combination treatments with sonic hedgehog inhibitors
JP2019176858A (ja) 薬物耐性ａｋｔ変異体を検出し治療するための方法及び組成物
JP6312660B2 (ja) Ｔｋ１タンパク質の発現が亢進した結腸直腸癌患者に対する治療効果予測方法
WO2022195551A1 (fr) Biomarqueurs pour le cancer et leurs méthodes d'utilisation
US10328062B2 (en) Biomarkers and use of MET inhibitor for treatment of cancer
US20150023920A1 (en) Novel compositions and methods for preventing or treating cancer metastasis
Bukhari Evaluating Synthetic Lethal Interactions in DNA Damage Signaling for Breast Cancer Therapy
WO2024211893A2 (fr) Méthodes et matériaux pour le traitement du cancer
JP2024509887A (ja) Ｅｐ３００分解剤および神経芽細胞腫におけるその使用

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20161222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20171012

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20180628

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015021877

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1079272

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190115

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: VOSSIUS AND PARTNER PATENTANWAELTE RECHTSANWAE, CH

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20181219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181219

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181219

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181219

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190319

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181219

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190319

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1079272

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181219

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181219

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190320

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181219

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190419

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181219

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181219

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181219

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181219

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181219

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181219

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190419

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015021877

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181219

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181219

26N No opposition filed

Effective date: 20190920

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181219

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181219

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190521

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190521

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181219

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20150521

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181219

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20220523

Year of fee payment: 8

Ref country code: FR

Payment date: 20220511

Year of fee payment: 8

Ref country code: DE

Payment date: 20220531

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20220523

Year of fee payment: 8

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230424

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602015021877

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20230521

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231201

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230521

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531